id,name,phase,indication,crossover,output_type,protocol,sap,created,last_updated,description,molecule,
701,NCT03529942,Phase 3,"Osteoarthritis, Knee",0,NA,NA,NA,2019-04-06 00:47:15,2019-04-06 00:47:15,NA,102,
700,NCT03104413,Phase 3,Crohn's Disease,0,,Protocol NCT03529942v1.0.doc,Statitical Analysis PlanNCT03529942v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee,1,
699,NCT03105102,Phase 3,Crohn's Disease,0,,Protocol NCT03104413v1.0.doc,Statitical Analysis PlanNCT03104413v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment,100,
698,NCT03107871,Phase 3,Cmv Congenital|CMV|Congenital Cmv|SNHL|Sensorineural Hearing Loss,0,,Protocol NCT03105102v1.0.doc,Statitical Analysis PlanNCT03105102v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991, or Completed M15-989,99
697,NCT03108846,Phase 3,Dementia,0,,Protocol NCT03107871v1.0.doc,Statitical Analysis PlanNCT03107871v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants,98,
696,NCT03126916,Phase 3,Childhood Ganglioneuroblastoma|Childhood Neuroblastoma|INRG Stage L2|INRG Stage M|INRG Stage MS|NMYC Gene Amplification|Recurrent Neuroblastoma,1,,Protocol NCT03108846v1.0.doc,Statitical Analysis PlanNCT03108846v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Escitalopram for Agitation in Alzheimer's Disease,97,
695,NCT03137173,Phase 3,Acute Bacterial Skin and Skin Structure Infections,0,,Protocol NCT03126916v1.0.doc,Statitical Analysis PlanNCT03126916v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,96,
694,NCT03150914,Phase 3,LAM|Lymphangioleiomyomatosis,0,,Protocol NCT03137173v1.0.doc,Statitical Analysis PlanNCT03137173v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections,95,
693,NCT03150589,Phase 3,Age-Related Macular Degeneration,1,,Protocol NCT03150914v1.0.doc,Statitical Analysis PlanNCT03150914v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial,94,
692,NCT03182907,Phase 3,Clostridium Difficile Infection,0,,Protocol NCT03150589v1.0.doc,Statitical Analysis PlanNCT03150589v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD),93,
691,NCT03192215,Phase 3,Stroke,0,,Protocol NCT03182907v1.0.doc,Statitical Analysis PlanNCT03182907v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001),92,
690,NCT03203447,Phase 3,Macular Edema|Retinal Vein Occlusion,0,,Protocol NCT03192215v1.0.doc,Statitical Analysis PlanNCT03192215v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke,91,
689,NCT03681184,Phase 3,Primary Hyperoxaluria Type 1 (PH1),0,,Protocol NCT03203447v1.0.doc,Statitical Analysis PlanNCT03203447v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO,90,
688,NCT03687255,Phase 3,Urinary Tract Infections,0,,Protocol NCT03681184v1.0.doc,Statitical Analysis PlanNCT03681184v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1,89,
687,NCT03399786,Phase 3,Homozygous Familial Hypercholesterolemia,0,,Protocol NCT03687255v1.0.doc,Statitical Analysis PlanNCT03687255v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections,88,
686,NCT03403205,Phase 3,Wilson Disease,0,,Protocol NCT03399786v1.0.doc,Statitical Analysis PlanNCT03399786v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia,87,
685,NCT03263494,Phase 3,Type 1 Diabetes Mellitus,0,,Protocol NCT03403205v1.0.doc,Statitical Analysis PlanNCT03403205v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects,86,
684,NCT03263026,Phase 3,Diffuse Large B-Cell Lymphoma,1,,Protocol NCT03263494v1.0.doc,Statitical Analysis PlanNCT03263494v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D),85,
683,NCT03283085,Phase 3,Crohn's Disease|Ulcerative Colitis,0,,Protocol NCT03263026v1.0.doc,Statitical Analysis PlanNCT03263026v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™,84,
682,NCT03286842,Phase 3,HER2-ve Metastatic Breast Cancer|Germline BRCA1/2 Mutations|Somatic BRCA1/2 Mutations,0,,Protocol NCT03283085v1.0.doc,Statitical Analysis PlanNCT03283085v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,A Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA),83,
681,NCT03290781,Phase 3,Ulcerative Colitis,0,,Protocol NCT03286842v1.0.doc,Statitical Analysis PlanNCT03286842v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.,82,
680,NCT03296813,Phase 3,Heart Failure,0,,Protocol NCT03290781v1.0.doc,Statitical Analysis PlanNCT03290781v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,An Efficacy and Safety Study of SHP647 as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis,81,
679,NCT03371017,Phase 3,Triple Negative Breast Neoplasms,0,,Protocol NCT03296813v1.0.doc,Statitical Analysis PlanNCT03296813v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure,80,
678,NCT03304054,Phase 3,"Myasthenia Gravis, Generalized",0,,Protocol NCT03371017v1.0.doc,Statitical Analysis PlanNCT03371017v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer,79,
677,NCT03306264,Phase 3,Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia,0,,Protocol NCT03304054v1.0.doc,Statitical Analysis PlanNCT03304054v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG,78,
676,NCT03494504,Phase 3,Allergic Conjunctivitis,0,,Protocol NCT03306264v1.0.doc,Statitical Analysis PlanNCT03306264v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Study of ASTX727 vs IV Decitabine in MDS and CMML,77,
675,NCT03500094,Phase 3,Fabry Disease,0,,Protocol NCT03494504v1.0.doc,Statitical Analysis PlanNCT03494504v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis,76,
674,NCT03312907,Phase 3,Systemic Lupus Erythematosus,0,,Protocol NCT03500094v1.0.doc,Statitical Analysis PlanNCT03500094v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,"Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)",75,
673,NCT03319849,Phase 3,Macular Telangiectasia Type 2,0,,Protocol NCT03312907v1.0.doc,Statitical Analysis PlanNCT03312907v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE,74,
672,NCT03334253,Phase 3,Myopia,0,,Protocol NCT03319849v1.0.doc,Statitical Analysis PlanNCT03319849v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,A Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2,73,
671,NCT03510897,Phase 3,Cardiac Surgery,0,,Protocol NCT03334253v1.0.doc,Statitical Analysis PlanNCT03334253v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Low-Dose Atropine for Treatment of Myopia,72,
670,NCT03512314,Phase 3,XIAP Deficiency|NLRC4-MAS,0,,Protocol NCT03510897v1.0.doc,Statitical Analysis PlanNCT03510897v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery,71,
669,NCT03329092,Phase 3,Complicated Intra-abdominal Infection|Hosptial Acquired Pneumonia|Ventilator Associated Pneumonia,0,,Protocol NCT03512314v1.0.doc,Statitical Analysis PlanNCT03512314v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension,70,
668,NCT03326843,Phase 3,Thrombocytopenia,0,,Protocol NCT03329092v1.0.doc,Statitical Analysis PlanNCT03329092v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,"A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.",69,
667,NCT03329508,Phase 3,Parkinson Disease,0,,Protocol NCT03326843v1.0.doc,Statitical Analysis PlanNCT03326843v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure,68,
666,NCT03334487,Phase 3,Small Cell Lung Cancer,0,,Protocol NCT03329508v1.0.doc,Statitical Analysis PlanNCT03329508v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,A Phase 3 Study With P2B001 in Subjects With Early Parkinson's,67,
665,NCT03350542,Phase 3,Coronary Artery Disease,0,,Protocol NCT03334487v1.0.doc,Statitical Analysis PlanNCT03334487v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer,66,
664,NCT03336619,Phase 3,Influenza,0,,Protocol NCT03350542v1.0.doc,Statitical Analysis PlanNCT03350542v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s),65,
663,NCT03342898,Phase 3,Dengue,0,,Protocol NCT03336619v1.0.doc,Statitical Analysis PlanNCT03336619v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza",64,
662,NCT03340727,Phase 3,Apnea of Prematurity,0,,Protocol NCT03342898v1.0.doc,Statitical Analysis PlanNCT03342898v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults,63,
661,NCT03345914,Phase 3,"Dermatitis, Atopic",0,,Protocol NCT03340727v1.0.doc,Statitical Analysis PlanNCT03340727v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Moderately Preterm Infants With Caffeine at Home for Apnea (MoCHA) Trial,62,
660,NCT03345823,Phase 3,Crohn's Disease,1,,Protocol NCT03345914v1.0.doc,Statitical Analysis PlanNCT03345914v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD),61,
659,NCT03345901,Phase 3,Diabetic Retinopathy|Diabetic Macular Edema,0,,Protocol NCT03345823v1.0.doc,Statitical Analysis PlanNCT03345823v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433,60,
658,NCT03417102,Phase 3,Hemophilia A|Hemophilia B,0,,Protocol NCT03345901v1.0.doc,Statitical Analysis PlanNCT03345901v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,PROMINENT-Eye Ancillary Study (Protocol AD),59,
657,NCT03525574,Phase 3,Cystic Fibrosis,0,,Protocol NCT03417102v1.0.doc,Statitical Analysis PlanNCT03417102v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors,58,
656,NCT03354273,Phase 3,Coronary Artery Disease (CAD),0,,Protocol NCT03525574v1.0.doc,Statitical Analysis PlanNCT03525574v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy,57,
655,NCT03526861,Phase 3,Atopic Dermatitis,0,,Protocol NCT03354273v1.0.doc,Statitical Analysis PlanNCT03354273v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD),56,
654,NCT03353753,Phase 3,Gastrointestinal Stromal Tumors,0,,Protocol NCT03526861v1.0.doc,Statitical Analysis PlanNCT03526861v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).,55,
653,NCT03354598,Phase 3,Uncomplicated Urinary Tract Infections,0,,Protocol NCT03353753v1.0.doc,Statitical Analysis PlanNCT03353753v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies,54,
652,NCT03364491,Phase 3,Obstetrical Complications|Hemorrhage|Labor and Delivery,0,,Protocol NCT03354598v1.0.doc,Statitical Analysis PlanNCT03354598v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women,53,
651,NCT03361501,Phase 3,Hypertriglyceridemia,0,,Protocol NCT03364491v1.0.doc,Statitical Analysis PlanNCT03364491v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean,52,
650,NCT03363854,Phase 3,Atopic Dermatitis,0,,Protocol NCT03361501v1.0.doc,Statitical Analysis PlanNCT03361501v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2),51,
649,NCT03363945,Phase 3,Kidney Transplant Rejection,0,,Protocol NCT03363854v1.0.doc,Statitical Analysis PlanNCT03363854v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3),50,
648,NCT03375320,Phase 3,Atypical Carcinoid Tumor|Carcinoid Tumor|Digestive System Neuroendocrine Neoplasm|Enterochromaffin Cell Serotonin-Producing Pancreatic Neuroendocrine Tumor|Functional Pancreatic Neuroendocrine Tumor|Intermediate Grade Lung Neuroendocrine Neoplasm|Low Grade Lung Neuroendocrine Neoplasm|Lung Atypical Carcinoid Tumor|Lung Carcinoid Tumor|Metastatic Digestive System Neuroendocrine Tumor G1|Neuroendocrine Neoplasm|Nonfunctional Pancreatic Neuroendocrine Tumor|Pancreatic Neuroendocrine Tumor|Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7|Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7|Stage IV Digestive System Neuroendocrine Tumor AJCC v7,0,,Protocol NCT03363945v1.0.doc,Statitical Analysis PlanNCT03363945v1.0.doc,2019-04-06 00:26:44,2019-04-06 00:26:44,"Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants",49,
647,NCT03376321,Phase 3,Influenza A,0,,Protocol NCT03375320v1.0.doc,Statitical Analysis PlanNCT03375320v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery",48,
646,NCT03400033,Phase 3,Anaemia,0,,Protocol NCT03376321v1.0.doc,Statitical Analysis PlanNCT03376321v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection",47,
645,NCT03377803,Phase 3,Molluscum Contagiosum,0,,Protocol NCT03400033v1.0.doc,Statitical Analysis PlanNCT03400033v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD),46,
644,NCT03377491,Phase 3,Pancreas Adenocarcinoma,0,,Protocol NCT03377803v1.0.doc,Statitical Analysis PlanNCT03377803v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Cantharidin Application in Molluscum Patients,45,
643,NCT03377790,Phase 3,Molluscum Contagiosum,0,,Protocol NCT03377491v1.0.doc,Statitical Analysis PlanNCT03377491v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)",44,
642,NCT03381196,Phase 3,Influenza A,0,,Protocol NCT03377790v1.0.doc,Statitical Analysis PlanNCT03377790v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Cantharidin Application in Molluscum Patients-1,43,
641,NCT03560466,Phase 3,Asthma,0,,Protocol NCT03381196v1.0.doc,Statitical Analysis PlanNCT03381196v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications",42,
640,NCT03386344,Phase 3,Type 2 Diabetes Mellitus,0,,Protocol NCT03560466v1.0.doc,Statitical Analysis PlanNCT03560466v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion),41,
639,NCT03386474,Phase 3,Neovascular Age-related Macular Degeneration,1,,Protocol NCT03386344v1.0.doc,Statitical Analysis PlanNCT03386344v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Efficacy and Bone Safety of Sotagliflozin Dose 1 and Dose 2 Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control,40,
638,NCT03386539,Phase 3,Pediatric Heart Transplantation|Immunosuppression|Chronic Kidney Diseases|Cardiac Allograft Vasculopathy|Heart Transplant Failure and Rejection|Post-transplant Lymphoproliferative Disorder|Heart Transplant Infection,0,,Protocol NCT03386474v1.0.doc,Statitical Analysis PlanNCT03386474v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD,39,
637,NCT03390504,Phase 3,Urothelial Cancer,0,,Protocol NCT03386539v1.0.doc,Statitical Analysis PlanNCT03386539v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score,38,
636,NCT03393000,Phase 3,Glioblastoma,0,,Protocol NCT03390504v1.0.doc,Statitical Analysis PlanNCT03390504v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations,37,
635,NCT03392974,Phase 3,Hemophilia A,0,,Protocol NCT03393000v1.0.doc,Statitical Analysis PlanNCT03393000v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects,36,
634,NCT03398005,Phase 3,Hypertriglyceridemia,0,,Protocol NCT03392974v1.0.doc,Statitical Analysis PlanNCT03392974v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg,35,
633,NCT03398135,Phase 3,Ulcerative Colitis (UC),1,,Protocol NCT03398005v1.0.doc,Statitical Analysis PlanNCT03398005v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1),34,
632,NCT03399604,Phase 3,Primary Pulmonary Hypertension,0,,Protocol NCT03398135v1.0.doc,Statitical Analysis PlanNCT03398135v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065,33,
631,NCT03400943,Phase 3,Leiomyoma,0,,Protocol NCT03399604v1.0.doc,Statitical Analysis PlanNCT03399604v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil,32,
630,NCT03400956,Phase 3,Leiomyoma,0,,Protocol NCT03400943v1.0.doc,Statitical Analysis PlanNCT03400943v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3),31,
629,NCT03401229,Phase 3,Nasal Polyposis,0,,Protocol NCT03400956v1.0.doc,Statitical Analysis PlanNCT03400956v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4),30,
628,NCT03417245,Phase 3,Hemophilia A|Hemophilia B,0,,Protocol NCT03401229v1.0.doc,Statitical Analysis PlanNCT03401229v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis,29,
627,NCT03403712,Phase 3,Chemotherapy-induced Nausea and Vomiting,0,,Protocol NCT03417245v1.0.doc,Statitical Analysis PlanNCT03417245v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors,28,
626,NCT03404401,Phase 3,Colonoscopy,1,,Protocol NCT03403712v1.0.doc,Statitical Analysis PlanNCT03403712v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer,27,
625,NCT03409614,Phase 3,Non-small Cell Lung Cancer,0,,Protocol NCT03404401v1.0.doc,Statitical Analysis PlanNCT03404401v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Safety and Efficacy Comparison of BLI4700 Bowel Prep Versus an FDA-approved Comparator in Adults Prior to Colonoscopy,26,
624,NCT03406156,Phase 3,Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL),0,,Protocol NCT03409614v1.0.doc,Statitical Analysis PlanNCT03409614v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer",25,
623,NCT03406078,Phase 3,Asthma,0,,Protocol NCT03406156v1.0.doc,Statitical Analysis PlanNCT03406156v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy",24,
622,NCT03587116,Phase 3,Hemophilia B,0,,Protocol NCT03406078v1.0.doc,Statitical Analysis PlanNCT03406078v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma,23,
621,NCT03409107,Phase 3,Anaemia,0,,Protocol NCT03587116v1.0.doc,Statitical Analysis PlanNCT03587116v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%),22,
620,NCT03410992,Phase 3,Chronic Plaque Psoriasis|Moderate to Severe Chronic Plaque Psoriasis|Psoriatic Arthritis,0,,Protocol NCT03409107v1.0.doc,Statitical Analysis PlanNCT03409107v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ),21,
619,NCT03412747,Phase 3,Chronic Plaque Psoriasis|Moderate to Severe Plaque Psoriasis,1,,Protocol NCT03410992v1.0.doc,Statitical Analysis PlanNCT03410992v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis,20,
618,NCT03414268,Phase 3,"Fasciitis, Plantar",0,,Protocol NCT03412747v1.0.doc,Statitical Analysis PlanNCT03412747v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis,19,
617,NCT03414255,Phase 3,Tendonitis,0,,Protocol NCT03414268v1.0.doc,Statitical Analysis PlanNCT03414268v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Micronized dHACM Injectable for the Treatment of Plantar Fasciitis,18,
616,NCT03415178,Phase 3,Hypercholesterolaemia,Achilles,1,,Protocol NCT03414255v1.0.doc,Statitical Analysis PlanNCT03414255v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Micronized dHACM Injectable for the Treatment of Achille Tendonitis,17
615,NCT03419403,Phase 3,Glioblastoma Multiforme,0,,Protocol NCT03415178v1.0.doc,Statitical Analysis PlanNCT03415178v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy,16,
614,NCT03414970,Phase 3,Ductal Breast Carcinoma|Invasive Breast Carcinoma|Lobular Breast Carcinoma|Medullary Breast Carcinoma|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Tubular Breast Carcinoma,0,,Protocol NCT03419403v1.0.doc,Statitical Analysis PlanNCT03419403v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study for Management of Ocular Side Effects in Subjects With Glioblastoma Receiving Depatuxizumab Mafodotin,15,
613,NCT03491462,Phase 3,Amyotrophic Lateral Sclerosis,0,,Protocol NCT03414970v1.0.doc,Statitical Analysis PlanNCT03414970v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer,14,
612,NCT03416179,Phase 3,"Leukemia, Myeloid, Acute",0,,Protocol NCT03491462v1.0.doc,Statitical Analysis PlanNCT03491462v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Arimoclomol in Amyotropic Lateral Sclerosis,13,
611,NCT03417037,Phase 3,Lung Cancer|Non-Small Cell Lung Cancer,0,,Protocol NCT03416179v1.0.doc,Statitical Analysis PlanNCT03416179v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia,12,
610,NCT03598790,Phase 3,Chronic Plaque Psoriasis|Moderate to Severe Chronic Plaque Psoriasis,0,,Protocol NCT03417037v1.0.doc,Statitical Analysis PlanNCT03417037v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer,11,
609,NCT03425539,Phase 3,Fabry Disease,0,,Protocol NCT03598790v1.0.doc,Statitical Analysis PlanNCT03598790v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"A Study to Assess the Safety, Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis",10,
608,NCT03420781,Phase 3,Gastroparesis|Diabetes Mellitus,0,,Protocol NCT03425539v1.0.doc,Statitical Analysis PlanNCT03425539v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease,9,
607,NCT03451292,Phase 3,Decompensated Cirrhosis and Ascites,1,,Protocol NCT03420781v1.0.doc,Statitical Analysis PlanNCT03420781v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03,8,
606,NCT03600818,Phase 3,Polymyalgia Rheumatica,0,,Protocol NCT03451292v1.0.doc,Statitical Analysis PlanNCT03451292v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites,7,
605,NCT03423173,Phase 3,Dengue Fever,0,,Protocol NCT03600818v1.0.doc,Statitical Analysis PlanNCT03600818v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica,6,
604,NCT03422653,Phase 3,Uremic Pruritus,0,,Protocol NCT03423173v1.0.doc,Statitical Analysis PlanNCT03423173v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue,5,
603,NCT03422822,Phase 3,"Dermatitis, Atopic",0,,Protocol NCT03422653v1.0.doc,Statitical Analysis PlanNCT03422653v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus,4,
602,NCT03425643,Phase 3,Non-small Cell Lung Cancer,0,,Protocol NCT03422822v1.0.doc,Statitical Analysis PlanNCT03422822v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis,3,
601,NCT03427814,Phase 3,Advanced or Inoperable Gastric Cancer,0,,Protocol NCT03425643v1.0.doc,Statitical Analysis PlanNCT03425643v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671),2,
600,NCT03426267,Phase 3,Inflammation and Pain Associated With Ocular Surgery,0,,Protocol NCT03427814v1.0.doc,Statitical Analysis PlanNCT03427814v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study of BGB-290 or Placebo in Patients With Advanced or Inoperable Gastric Cancer,1,
599,NCT03426345,Phase 3,Gastroparesis|Diabetes Mellitus,0,,Protocol NCT03426267v1.0.doc,Statitical Analysis PlanNCT03426267v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Evaluation of Efficacy and Safety of SDN-037,100,
598,NCT03440814,Phase 3,Prader-Willi Syndrome,0,,Protocol NCT03426345v1.0.doc,Statitical Analysis PlanNCT03426345v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02,99,
597,NCT03428750,Phase 3,Edematous Fibrosclerotic Panniculopathy (Cellulite),0,,Protocol NCT03440814v1.0.doc,Statitical Analysis PlanNCT03440814v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome,98,
596,NCT03429049,Phase 3,Osteo Arthritis Knee,0,,Protocol NCT03428750v1.0.doc,Statitical Analysis PlanNCT03428750v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women,97,
595,NCT03429543,Phase 3,"Diabetes Mellitus, Type 2",0,,Protocol NCT03429049v1.0.doc,Statitical Analysis PlanNCT03429049v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Clinical Study to Test Efficacy and Safety of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain,96,
594,NCT03461211,Phase 3,Thyroid Eye Disease,0,,Protocol NCT03429543v1.0.doc,Statitical Analysis PlanNCT03429543v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM,95,
593,NCT03442751,Phase 3,Progressive Keratoconus,0,,Protocol NCT03461211v1.0.doc,Statitical Analysis PlanNCT03461211v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study,94,
592,NCT03614234,Phase 3,Fabry Disease,0,,Protocol NCT03442751v1.0.doc,Statitical Analysis PlanNCT03442751v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus,93,
591,NCT03432286,Phase 3,Episodic Migraine,0,,Protocol NCT03614234v1.0.doc,Statitical Analysis PlanNCT03614234v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients,92,
590,NCT03432533,Phase 3,Post-Menopausal Osteoporosis,0,,Protocol NCT03432286v1.0.doc,Statitical Analysis PlanNCT03432286v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine,91,
589,NCT03434028,Phase 3,Septic Shock,0,,Protocol NCT03432533v1.0.doc,Statitical Analysis PlanNCT03432533v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis,90,
588,NCT03434119,Phase 3,Type 2 Diabetes Mellitus,0,,Protocol NCT03434028v1.0.doc,Statitical Analysis PlanNCT03434028v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis,89,
587,NCT03434379,Phase 3,"Carcinoma, Hepatocellular",0,,Protocol NCT03434119v1.0.doc,Statitical Analysis PlanNCT03434119v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents,88,
586,NCT03435081,Phase 3,Atopic Dermatitis,0,,Protocol NCT03434379v1.0.doc,Statitical Analysis PlanNCT03434379v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150],87,
585,NCT03509350,Phase 3,Sepsis,0,,Protocol NCT03435081v1.0.doc,Statitical Analysis PlanNCT03435081v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis,86,
584,NCT03436199,Phase 3,Walking Impairment|Multiple Sclerosis,0,,Protocol NCT03509350v1.0.doc,Statitical Analysis PlanNCT03509350v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"Vitamin C, Thiamine, and Steroids in Sepsis",85,
583,NCT03439514,Phase 3,Dilated Cardiomyopathy|Lamin A/C Gene Mutation,1,,Protocol NCT03436199v1.0.doc,Statitical Analysis PlanNCT03436199v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment,84,
582,NCT03440372,Phase 3,Crohn Disease,0,,Protocol NCT03439514v1.0.doc,Statitical Analysis PlanNCT03439514v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation,83,
581,NCT03440385,Phase 3,Crohn Disease,0,,Protocol NCT03440372v1.0.doc,Statitical Analysis PlanNCT03440372v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease,82,
580,NCT03471078,Phase 3,Chemotherapy-induced Thrombocytopenia,0,,Protocol NCT03440385v1.0.doc,Statitical Analysis PlanNCT03440385v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease,81,
579,NCT03443869,Phase 3,CMV Disease,0,,Protocol NCT03471078v1.0.doc,Statitical Analysis PlanNCT03471078v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers,80,
578,NCT03443973,Phase 3,Alzheimer's Disease,0,,Protocol NCT03443869v1.0.doc,Statitical Analysis PlanNCT03443869v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002),79,
577,NCT03444870,Phase 3,Alzheimer Disease,0,,Protocol NCT03443973v1.0.doc,Statitical Analysis PlanNCT03443973v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD),78,
576,NCT03445533,Phase 3,Metastatic Melanoma,0,,Protocol NCT03444870v1.0.doc,Statitical Analysis PlanNCT03444870v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD),77,
575,NCT03451851,Phase 3,Psoriasis,0,,Protocol NCT03445533v1.0.doc,Statitical Analysis PlanNCT03445533v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301),76,
574,NCT03446573,Phase 3,"Infection, Human Immunodeficiency Virus",0,,Protocol NCT03451851v1.0.doc,Statitical Analysis PlanNCT03451851v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants",75,
573,NCT03446781,Phase 3,Edematous Fibrosclerotic Panniculopathy (Cellulite),0,,Protocol NCT03446573v1.0.doc,Statitical Analysis PlanNCT03446573v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO),74,
572,NCT03447249,Phase 3,Cystic Fibrosis,0,,Protocol NCT03446781v1.0.doc,Statitical Analysis PlanNCT03446781v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women,73,
571,NCT03447262,Phase 3,Cystic Fibrosis,0,,Protocol NCT03447249v1.0.doc,Statitical Analysis PlanNCT03447249v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF),72,
570,NCT03447769,Phase 3,Non-Small Cell Lung Cancer,0,,Protocol NCT03447262v1.0.doc,Statitical Analysis PlanNCT03447262v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy,71,
569,NCT03448406,Phase 3,Heart Failure,0,,Protocol NCT03447769v1.0.doc,Statitical Analysis PlanNCT03447769v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: (None),70,
568,NCT03448419,Phase 3,Heart Failure,0,,Protocol NCT03448406v1.0.doc,Statitical Analysis PlanNCT03448406v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.,69,
567,NCT03449134,Phase 3,Chronic Cough,0,,Protocol NCT03448419v1.0.doc,Statitical Analysis PlanNCT03448419v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms,68,
566,NCT03449147,Phase 3,Chronic Cough,0,,Protocol NCT03449134v1.0.doc,Statitical Analysis PlanNCT03449134v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Phase 3 Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027),67,
565,NCT03519945,Phase 3,Ulcerative Colitis,0,,Protocol NCT03449147v1.0.doc,Statitical Analysis PlanNCT03449147v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030),66,
564,NCT03450629,Phase 3,Open Angle Glaucoma|Ocular Hypertension,0,,Protocol NCT03519945v1.0.doc,Statitical Analysis PlanNCT03519945v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3),65,
563,NCT03452137,Phase 3,Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN),0,,Protocol NCT03450629v1.0.doc,Statitical Analysis PlanNCT03450629v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Evaluation of Safety and Efficacy of Brimonidine Tartrate Ophthalmic Suspension,64,
562,NCT03523117,Phase 3,Iron Deficiency Anemia,1,,Protocol NCT03452137v1.0.doc,Statitical Analysis PlanNCT03452137v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck,63,
561,NCT03456063,Phase 3,Non-Small-Cell Lung,0,,Protocol NCT03523117v1.0.doc,Statitical Analysis PlanNCT03523117v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA,62,
560,NCT03456336,Phase 3,"Infant, Premature|Patent Ductus Arteriosus|Infant, Newborn, Diseases|Patent Ductus Arteriosus After Premature Birth",0,,Protocol NCT03456063v1.0.doc,Statitical Analysis PlanNCT03456063v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)",61,
559,NCT03456830,Phase 3,Enteric Hyperoxaluria,0,,Protocol NCT03456336v1.0.doc,Statitical Analysis PlanNCT03456336v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Management of the PDA Trial,60,
558,NCT03460652,Phase 3,ADHD,0,,Protocol NCT03456830v1.0.doc,Statitical Analysis PlanNCT03456830v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria,59,
557,NCT03460990,Phase 3,Cystic Fibrosis,0,,Protocol NCT03460652v1.0.doc,Statitical Analysis PlanNCT03460652v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD,58,
556,NCT03528577,Phase 3,Asthma,1,,Protocol NCT03460990v1.0.doc,Statitical Analysis PlanNCT03460990v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F),57,
555,NCT03461757,Phase 3,Migraine,0,,Protocol NCT03528577v1.0.doc,Statitical Analysis PlanNCT03528577v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)",56,
554,NCT03463031,Phase 3,Seasonal Allergic Rhinitis (SAR),0,,Protocol NCT03461757v1.0.doc,Statitical Analysis PlanNCT03461757v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Trial in Adult Subjects With Acute Migraines,55,
553,NCT03464019,Phase 3,Paroxysmal Supraventricular Tachycardia,0,,Protocol NCT03463031v1.0.doc,Statitical Analysis PlanNCT03463031v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR),54,
552,NCT03464097,Phase 3,Crohn Disease,0,,Protocol NCT03464019v1.0.doc,Statitical Analysis PlanNCT03464019v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301,53,
551,NCT03464136,Phase 3,Crohn Disease,0,,Protocol NCT03464097v1.0.doc,Statitical Analysis PlanNCT03464097v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease,52,
550,NCT03465722,Phase 3,GIST,0,,Protocol NCT03464136v1.0.doc,Statitical Analysis PlanNCT03464136v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year,51,
549,NCT03466411,Phase 3,Crohn's Disease,1,,Protocol NCT03465722v1.0.doc,Statitical Analysis PlanNCT03465722v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST,50,
548,NCT03482011,Phase 3,Psoriasis,0,,Protocol NCT03466411v1.0.doc,Statitical Analysis PlanNCT03466411v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease,49,
547,NCT03470545,Phase 3,Obstructive Hypertrophic Cardiomyopathy,0,,Protocol NCT03482011v1.0.doc,Statitical Analysis PlanNCT03482011v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis,48,
546,NCT03486873,Phase 3,Solid Tumors,0,,Protocol NCT03470545v1.0.doc,Statitical Analysis PlanNCT03470545v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy,47,
545,NCT03473223,Phase 3,Acute Coronary Syndrome,0,,Protocol NCT03486873v1.0.doc,Statitical Analysis PlanNCT03486873v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587),46,
544,NCT03474107,Phase 3,Ureteral Cancer|Urothelial Cancer|Bladder Cancer,0,,Protocol NCT03473223v1.0.doc,Statitical Analysis PlanNCT03473223v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome,45,
543,NCT03505723,Phase 3,Perioperative Bleeding|Venous Thrombosis|Arterial Thrombosis,0,,Protocol NCT03474107v1.0.doc,Statitical Analysis PlanNCT03474107v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301),44,
542,NCT03478787,Phase 3,Psoriasis,1,,Protocol NCT03505723v1.0.doc,Statitical Analysis PlanNCT03505723v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,PeriOperative ISchemic Evaluation-3 Trial,43,
541,NCT03478930,Phase 3,Nasal Polyps|Chronic Rhinosinusitis,0,,Protocol NCT03478787v1.0.doc,Statitical Analysis PlanNCT03478787v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis,42,
540,NCT03480763,Phase 3,Pneumococcal Infections,0,,Protocol NCT03478930v1.0.doc,Statitical Analysis PlanNCT03478930v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps,41,
539,NCT03481634,Phase 3,Diabetic Macular Edema,1,,Protocol NCT03480763v1.0.doc,Statitical Analysis PlanNCT03480763v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",40,
538,NCT03495921,Phase 3,Ewing Sarcoma|Ewing Family of Tumors|Ewing's Tumor Metastatic|Ewing's Sarcoma Metastatic,0,,Protocol NCT03481634v1.0.doc,Statitical Analysis PlanNCT03481634v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema,39,
537,NCT03485911,Phase 3,Hereditary Angioedema|HAE,0,,Protocol NCT03495921v1.0.doc,Statitical Analysis PlanNCT03495921v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma,38,
536,NCT03491150,Phase 3,Alzheimer's Disease,0,,Protocol NCT03485911v1.0.doc,Statitical Analysis PlanNCT03485911v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE,37,
535,NCT03492281,Phase 3,Overactive Bladder,0,,Protocol NCT03491150v1.0.doc,Statitical Analysis PlanNCT03491150v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,An Open-Label Crenezumab Study in Patients With Alzheimer's Disease,36,
534,NCT03493685,Phase 3,Focal Segmental Glomerulosclerosis,0,,Protocol NCT03492281v1.0.doc,Statitical Analysis PlanNCT03492281v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB),35,
533,NCT03493854,Phase 3,Early Breast Cancer,0,,Protocol NCT03493685v1.0.doc,Statitical Analysis PlanNCT03493685v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study of Sparsentan in FSGS,34,
532,NCT03495102,Phase 3,"Diabetes Mellitus, Type 2",0,,Protocol NCT03493854v1.0.doc,Statitical Analysis PlanNCT03493854v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer",33,
531,NCT03496298,Phase 3,Type 2 Diabetes Mellitus,0,,Protocol NCT03495102v1.0.doc,Statitical Analysis PlanNCT03495102v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes,32,
530,NCT03496623,Phase 3,Pulmonary Hypertension|Chronic Obstructive Pulmonary Disease,1,,Protocol NCT03496298v1.0.doc,Statitical Analysis PlanNCT03496298v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Effect of Efpeglenatide on Cardiovascular Outcomes,31,
529,NCT03498716,Phase 3,Triple Negative Breast Cancer,0,,Protocol NCT03496623v1.0.doc,Statitical Analysis PlanNCT03496623v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With PH Due to COPD,30,
528,NCT03502616,Phase 3,Ankylosing Spondylitis,0,,Protocol NCT03498716v1.0.doc,Statitical Analysis PlanNCT03498716v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer,29,
527,NCT03501966,Phase 3,Idiopathic Intracranial Hypertension,0,,Protocol NCT03502616v1.0.doc,Statitical Analysis PlanNCT03502616v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS),28,
526,NCT03503318,Phase 3,Schizophrenia,0,,Protocol NCT03501966v1.0.doc,Statitical Analysis PlanNCT03501966v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Surgical Idiopathic Intracranial Hypertension Treatment Trial,27,
525,NCT03504397,Phase 3,Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer|Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer|Metastatic Gastric Adenocarcinoma or Cancer|Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma,0,,Protocol NCT03503318v1.0.doc,Statitical Analysis PlanNCT03503318v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Evaluate TV-46000 as Maintenance Treatment in Adult Patients With Schizophrenia,26,
524,NCT03504917,Phase 3,Autism Spectrum Disorder,0,,Protocol NCT03504397v1.0.doc,Statitical Analysis PlanNCT03504397v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"A Study to Assess the Efficacy of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN) 18.2 Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",25,
523,NCT03505021,Phase 3,Amyotrophic Lateral Sclerosis,0,,Protocol NCT03504917v1.0.doc,Statitical Analysis PlanNCT03504917v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension,24,
522,NCT03505099,Phase 3,Spinal Muscular Atrophy,0,,Protocol NCT03505021v1.0.doc,Statitical Analysis PlanNCT03505021v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,23,
521,NCT03515837,Phase 3,Non-small Cell Lung Cancer,0,,Protocol NCT03505099v1.0.doc,Statitical Analysis PlanNCT03505099v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Pre-Symptomatic Study of Intravenous AVXS-101 in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2,22,
520,NCT03511664,Phase 3,Prostate Cancer,0,,Protocol NCT03515837v1.0.doc,Statitical Analysis PlanNCT03515837v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789),21,
519,NCT03508700,Phase 3,PTSD,0,,Protocol NCT03511664v1.0.doc,Statitical Analysis PlanNCT03511664v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer,20,
518,NCT03515629,Phase 3,Non-small Cell Lung Cancer,0,,Protocol NCT03508700v1.0.doc,Statitical Analysis PlanNCT03508700v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD,19,
517,NCT03522441,Phase 3,Acne Vulgaris,0,,Protocol NCT03515629v1.0.doc,Statitical Analysis PlanNCT03515629v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer",18,
516,NCT03517449,Phase 3,Endometrial Neoplasms,0,,Protocol NCT03522441v1.0.doc,Statitical Analysis PlanNCT03522441v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris,17,
515,NCT03517722,Phase 3,"Lupus Erythematosus, Systemic",0,,Protocol NCT03517449v1.0.doc,Statitical Analysis PlanNCT03517449v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]),16,
514,NCT03518086,Phase 3,Ulcerative Colitis,0,,Protocol NCT03517722v1.0.doc,Statitical Analysis PlanNCT03517722v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus,15,
513,NCT03520959,Phase 3,Synovial Sarcoma|Cancer|Soft Tissue Sarcoma|Sarcoma|Metastatic Sarcoma,0,,Protocol NCT03518086v1.0.doc,Statitical Analysis PlanNCT03518086v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1),14,
512,NCT03521934,Phase 3,Heart Failure-Type 2 Diabetes Mellitus,0,,Protocol NCT03520959v1.0.doc,Statitical Analysis PlanNCT03520959v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"Synovate Study for Synovial Sarcoma, Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma",13,
511,NCT03522246,Phase 3,Epithelial Ovarian Cancer|Primary Peritoneal|Fallopian Tube Cancer|Newly Diagnosed|FIGO Stage III-IV|Partial Response|Complete Response,0,,Protocol NCT03521934v1.0.doc,Statitical Analysis PlanNCT03521934v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial),12,
510,NCT03523858,Phase 3,Progressive Multiple Sclerosis (PMS),0,,Protocol NCT03522246v1.0.doc,Statitical Analysis PlanNCT03522246v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy,11,
509,NCT03524092,Phase 3,Ulcerative Colitis,0,,Protocol NCT03523858v1.0.doc,Statitical Analysis PlanNCT03523858v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis,10,
508,NCT03525444,Phase 3,Cystic Fibrosis,0,,Protocol NCT03524092v1.0.doc,Statitical Analysis PlanNCT03524092v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis,9,
507,NCT03525548,Phase 3,Cystic Fibrosis,0,,Protocol NCT03525444v1.0.doc,Statitical Analysis PlanNCT03525444v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF),8,
506,NCT03525600,Phase 3,Geographic Atrophy,1,,Protocol NCT03525548v1.0.doc,Statitical Analysis PlanNCT03525548v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F),7,
505,NCT03525613,Phase 3,Geographic Atrophy,0,,Protocol NCT03525600v1.0.doc,Statitical Analysis PlanNCT03525600v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration,6,
504,NCT03553836,Phase 3,Melanoma,0,,Protocol NCT03525613v1.0.doc,Statitical Analysis PlanNCT03525613v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD),5,
503,NCT03526549,Phase 3,Edematous Fibrosclerotic Panniculopathy|Cellulite,0,,Protocol NCT03553836v1.0.doc,Statitical Analysis PlanNCT03553836v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716),4,
502,NCT03528551,Phase 3,Congenital Bleeding Disorder|Haemophilia A,0,,Protocol NCT03526549v1.0.doc,Statitical Analysis PlanNCT03526549v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Long-Term Study of EN3835 in Edematous Fibrosclerotic Panniculopathy (Cellulite),3,
501,NCT03530345,Phase 3,Complex Regional Pain Syndrome (CRPS),0,,Protocol NCT03528551v1.0.doc,Statitical Analysis PlanNCT03528551v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A,2,
500,NCT03537014,Phase 3,Posttraumatic Stress Disorder,0,,Protocol NCT03530345v1.0.doc,Statitical Analysis PlanNCT03530345v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Efficacy and Safety of Intravenous Neridronic Acid in CRPS,1,
499,NCT03535194,Phase 3,Psoriasis,0,,Protocol NCT03537014v1.0.doc,Statitical Analysis PlanNCT03537014v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD,100,
498,NCT03536884,Phase 3,Chronic Plaque Psoriasis|Moderate to Severe Chronic Plaque Psoriasis,0,,Protocol NCT03535194v1.0.doc,Statitical Analysis PlanNCT03535194v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2),99,
497,NCT03536949,Phase 3,Blepharoptosis,0,,Protocol NCT03536884v1.0.doc,Statitical Analysis PlanNCT03536884v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis,98,
496,NCT03537508,Phase 3,Meningococcal Infections,0,,Protocol NCT03536949v1.0.doc,Statitical Analysis PlanNCT03536949v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study of Safety of RVL-1201 in Treatment of Blepharoptosis,97,
495,NCT03537651,Phase 3,Cystic Fibrosis,0,,Protocol NCT03537508v1.0.doc,Statitical Analysis PlanNCT03537508v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US,96,
494,NCT03539744,Phase 3,Multiple Myeloma,0,,Protocol NCT03537651v1.0.doc,Statitical Analysis PlanNCT03537651v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Subjects With an F508del CFTR Mutation,95,
493,NCT03538691,Phase 3,Major Depressive Disorder,0,,Protocol NCT03539744v1.0.doc,Statitical Analysis PlanNCT03539744v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma,94,
492,NCT03540160,Phase 3,Pruritus|Prurigo Nodularis|Atopic Dermatitis|Psoriasis,0,,Protocol NCT03538691v1.0.doc,Statitical Analysis PlanNCT03538691v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder",93,
491,NCT03541174,Phase 3,Resistant Hypertension,0,,Protocol NCT03540160v1.0.doc,Statitical Analysis PlanNCT03540160v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch),92,
490,NCT03548220,Phase 3,"Pyruvate Kinase Deficiency|Anemia, Hemolytic",0,,Protocol NCT03541174v1.0.doc,Statitical Analysis PlanNCT03541174v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety,91,
489,NCT03545191,Phase 3,Insomnia Disorder,0,,Protocol NCT03548220v1.0.doc,Statitical Analysis PlanNCT03548220v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD),90,
488,NCT03546816,Phase 3,Pruritus|Prurigo Nodularis,0,,Protocol NCT03545191v1.0.doc,Statitical Analysis PlanNCT03545191v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder,89,
487,NCT03547167,Phase 3,Pneumococcal Infections,0,,Protocol NCT03546816v1.0.doc,Statitical Analysis PlanNCT03546816v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis",88,
486,NCT03547908,Phase 3,HIV-1/HBV Co-Infection,0,,Protocol NCT03547167v1.0.doc,Statitical Analysis PlanNCT03547167v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)",87,
485,NCT03548584,Phase 3,Agitaton Associated With Alzheimer's Dementia|Alzheimer Dementia,1,,Protocol NCT03547908v1.0.doc,Statitical Analysis PlanNCT03547908v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults",86,
484,NCT03548935,Phase 3,Metabolism and Nutrition Disorder|Overweight or Obesity,0,,Protocol NCT03548584v1.0.doc,Statitical Analysis PlanNCT03548584v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type",85,
483,NCT03548987,Phase 3,Metabolism and Nutrition Disorder|Obesity,0,,Protocol NCT03548935v1.0.doc,Statitical Analysis PlanNCT03548935v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity,84,
482,NCT03551496,Phase 3,Critical Limb Ischemia,0,,Protocol NCT03548987v1.0.doc,Statitical Analysis PlanNCT03548987v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity,83,
481,NCT03566017,Phase 3,Fabry Disease,0,,Protocol NCT03551496v1.0.doc,Statitical Analysis PlanNCT03551496v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia,82,
480,NCT03552757,Phase 3,Obesity|Overweight,0,,Protocol NCT03566017v1.0.doc,Statitical Analysis PlanNCT03566017v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Extension Study of 1 mg/kg Pegunigalsidase Alfa in Patients With Fabry Disease,81,
479,NCT03556202,Phase 3,Psoriasis,1,,Protocol NCT03552757v1.0.doc,Statitical Analysis PlanNCT03552757v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity,80,
478,NCT03557307,Phase 3,Asthma,0,,Protocol NCT03556202v1.0.doc,Statitical Analysis PlanNCT03556202v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3),79,
477,NCT03557333,Phase 3,Migraine Headache,0,,Protocol NCT03557307v1.0.doc,Statitical Analysis PlanNCT03557307v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma,78,
476,NCT03559010,Phase 3,Contraception,0,,Protocol NCT03557333v1.0.doc,Statitical Analysis PlanNCT03557333v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP-301),77,
475,NCT03559257,Phase 3,Migraine,0,,Protocol NCT03559010v1.0.doc,Statitical Analysis PlanNCT03559010v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Oral Contraception Under Simulated OTC Conditions,76,
474,NCT03559270,Phase 3,Atopic Dermatitis,0,,Protocol NCT03559257v1.0.doc,Statitical Analysis PlanNCT03559257v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine,75,
473,NCT03559517,Phase 3,Crohn's Disease,0,,Protocol NCT03559270v1.0.doc,Statitical Analysis PlanNCT03559270v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis,74,
472,NCT03560518,Phase 3,"Depressive Disorder, Major",1,,Protocol NCT03559517v1.0.doc,Statitical Analysis PlanNCT03559517v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305),73,
471,NCT03561701,Phase 3,Recurrent Vulvovaginal Candidiasis,0,,Protocol NCT03560518v1.0.doc,Statitical Analysis PlanNCT03560518v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study of Rapastinel as Monotherapy in Patients With MDD,72,
470,NCT03562637,Phase 3,Triple Negative Breast Cancer,0,,Protocol NCT03561701v1.0.doc,Statitical Analysis PlanNCT03561701v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection),71,
469,NCT03560986,Phase 3,Complex Regional Pain Syndrome (CRPS),0,,Protocol NCT03562637v1.0.doc,Statitical Analysis PlanNCT03562637v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy.,70,
468,NCT03561090,Phase 3,Gastroesophageal Reflux Disease (GERD),0,,Protocol NCT03560986v1.0.doc,Statitical Analysis PlanNCT03560986v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS),69,
467,NCT03561883,Phase 3,Gastroesophageal Reflux Disease (GERD),0,,Protocol NCT03561090v1.0.doc,Statitical Analysis PlanNCT03561090v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors,68,
466,NCT03562156,Phase 3,Recurrent Vulvovaginal Candidiasis,0,,Protocol NCT03561883v1.0.doc,Statitical Analysis PlanNCT03561883v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors,67,
465,NCT03565211,Phase 3,Progesterone Supplementation in Women Undergoing ART,1,,Protocol NCT03562156v1.0.doc,Statitical Analysis PlanNCT03562156v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection),66,
464,NCT03571256,Phase 3,Tourette Syndrome,0,,Protocol NCT03565211v1.0.doc,Statitical Analysis PlanNCT03565211v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Clinical Safety Study of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology Procedures,65,
463,NCT03565887,Phase 3,Blepharoptosis,0,,Protocol NCT03571256v1.0.doc,Statitical Analysis PlanNCT03571256v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome,64,
462,NCT03569891,Phase 3,Hemophilia B,1,,Protocol NCT03565887v1.0.doc,Statitical Analysis PlanNCT03565887v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis,63,
461,NCT03566823,Phase 3,Crohn's Disease,0,,Protocol NCT03569891v1.0.doc,Statitical Analysis PlanNCT03569891v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients,62,
460,NCT03568318,Phase 3,Atopic Dermatitis,0,,Protocol NCT03566823v1.0.doc,Statitical Analysis PlanNCT03566823v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306),61,
459,NCT03568331,Phase 3,Atopic Dermatitis,0,,Protocol NCT03568318v1.0.doc,Statitical Analysis PlanNCT03568318v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis,60,
458,NCT03569293,Phase 3,Atopic Dermatitis,0,,Protocol NCT03568331v1.0.doc,Statitical Analysis PlanNCT03568331v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis,59,
457,NCT03569475,Phase 3,Major Depressive Disorder,0,,Protocol NCT03569293v1.0.doc,Statitical Analysis PlanNCT03569293v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)- Measure Up 1,58,
456,NCT03575052,Phase 3,Neuropsychiatric Symptoms Related to Neurodegenerative Disease,0,,Protocol NCT03569475v1.0.doc,Statitical Analysis PlanNCT03569475v1.0.doc,2019-04-06 00:26:43,2019-04-06 00:26:43,"Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric (7-17 Years) With Major Depressive Disorder",57,
455,NCT03573297,Phase 3,Bipolar I Disorder|Mania|Depression,0,,Protocol NCT03575052v1.0.doc,Statitical Analysis PlanNCT03575052v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease,56,
454,NCT03573908,Phase 3,Irritable Bowel Syndrome Characterized by Constipation,0,,Protocol NCT03573297v1.0.doc,Statitical Analysis PlanNCT03573297v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features",55,
453,NCT03574597,Phase 3,Overweight|Obesity,1,,Protocol NCT03573908v1.0.doc,Statitical Analysis PlanNCT03573908v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation,54,
452,NCT03575104,Phase 3,Insomnia Disorder,0,,Protocol NCT03574597v1.0.doc,Statitical Analysis PlanNCT03574597v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity,53,
451,NCT03575351,Phase 3,"Lymphoma, Non-Hodgkin",0,,Protocol NCT03575104v1.0.doc,Statitical Analysis PlanNCT03575104v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep,52,
450,NCT03577899,Phase 3,Neovascular Age-related Macular Degeneration,0,,Protocol NCT03575351v1.0.doc,Statitical Analysis PlanNCT03575351v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas",51,
449,NCT03575871,Phase 3,"Dermatitis, Atopic",0,,Protocol NCT03577899v1.0.doc,Statitical Analysis PlanNCT03577899v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration (PANDA-1),50,
448,NCT03579459,Phase 3,Clostridium Difficile Associated Disease,0,,Protocol NCT03575871v1.0.doc,Statitical Analysis PlanNCT03575871v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis,49,
447,NCT03579966,Phase 3,"Myasthenia Gravis, MuSK",0,,Protocol NCT03579459v1.0.doc,Statitical Analysis PlanNCT03579459v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age,48,
446,NCT03592472,Phase 3,Renal Cell Carcinoma,0,,Protocol NCT03579966v1.0.doc,Statitical Analysis PlanNCT03579966v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis),47,
445,NCT03583372,Phase 3,Overactive Bladder,0,,Protocol NCT03592472v1.0.doc,Statitical Analysis PlanNCT03592472v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV),46,
444,NCT03585270,Phase 3,Aneurysmal Subarachnoid Hemorrhage,0,,Protocol NCT03583372v1.0.doc,Statitical Analysis PlanNCT03583372v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).,45,
443,NCT03588975,Phase 3,Chondral Defect|Osteochondritis Dissecans|Articular Cartilage Defect|Articular Cartilage Disorder of Knee,0,,Protocol NCT03585270v1.0.doc,Statitical Analysis PlanNCT03585270v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain",44,
442,NCT03587805,Phase 3,Atopic Dermatitis,0,,Protocol NCT03588975v1.0.doc,Statitical Analysis PlanNCT03588975v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study of MACI in Patients Aged 10 to <17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee,43,
441,NCT03593213,Phase 3,Schizophrenia,0,,Protocol NCT03587805v1.0.doc,Statitical Analysis PlanNCT03587805v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND,42,
440,NCT03608397,Phase 3,Cervical Dystonia,0,,Protocol NCT03593213v1.0.doc,Statitical Analysis PlanNCT03593213v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia",41,
439,NCT03596645,Phase 3,"Colitis, Ulcerative",0,,Protocol NCT03608397v1.0.doc,Statitical Analysis PlanNCT03608397v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1),40,
438,NCT03597503,Phase 3,Attention Deficit Hyperactivity Disorder,0,,Protocol NCT03596645v1.0.doc,Statitical Analysis PlanNCT03596645v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis,39,
437,NCT03597516,Phase 3,Lactose Intolerance,0,,Protocol NCT03597503v1.0.doc,Statitical Analysis PlanNCT03597503v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment,38,
436,NCT03601637,Phase 3,Cystic Fibrosis,0,,Protocol NCT03597516v1.0.doc,Statitical Analysis PlanNCT03597516v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance",37,
435,NCT03619005,Phase 3,Hypoactive Sexual Desire Disorder (HSDD),0,,Protocol NCT03601637v1.0.doc,Statitical Analysis PlanNCT03601637v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del",36,
434,NCT03602560,Phase 3,Primary Biliary Cholangitis,0,,Protocol NCT03619005v1.0.doc,Statitical Analysis PlanNCT03619005v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study,35,
433,NCT03605862,Phase 3,Enterovirus|Rhinovirus,0,,Protocol NCT03602560v1.0.doc,Statitical Analysis PlanNCT03602560v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA),34,
432,NCT03607422,Phase 3,Atopic Dermatitis,0,,Protocol NCT03605862v1.0.doc,Statitical Analysis PlanNCT03605862v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection,33,
431,NCT03607838,Phase 3,Lumbar Disc Herniation,0,,Protocol NCT03607422v1.0.doc,Statitical Analysis PlanNCT03607422v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis,32,
430,NCT03608033,Phase 3,IgA Nephropathy,0,,Protocol NCT03607838v1.0.doc,Statitical Analysis PlanNCT03607838v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,SI-6603 (Condoliase) Study for Lumbar Disc Herniation,31,
429,NCT03610646,Phase 3,Diabetic Macular Edema,1,,Protocol NCT03608033v1.0.doc,Statitical Analysis PlanNCT03608033v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy,30,
428,NCT03650361,Phase 3,Acne Vulgaris,0,,Protocol NCT03610646v1.0.doc,Statitical Analysis PlanNCT03610646v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema,29,
427,NCT03611582,Phase 3,Overweight|Obesity,0,,Protocol NCT03650361v1.0.doc,Statitical Analysis PlanNCT03650361v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris,28,
426,NCT03611751,Phase 3,Psoriasis,0,,Protocol NCT03611582v1.0.doc,Statitical Analysis PlanNCT03611582v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program,27,
425,NCT03614156,Phase 3,"Depressive Disorder, Major",0,,Protocol NCT03611751v1.0.doc,Statitical Analysis PlanNCT03611751v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis,26,
424,NCT03615482,Phase 3,Pneumococcal Infections,0,,Protocol NCT03614156v1.0.doc,Statitical Analysis PlanNCT03614156v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD),25,
423,NCT03615924,Phase 3,Sickle Cell Disease,0,,Protocol NCT03615482v1.0.doc,Statitical Analysis PlanNCT03615482v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)",24,
422,NCT03616899,Phase 3,Kerato Conjunctivitis Sicca,0,,Protocol NCT03615924v1.0.doc,Statitical Analysis PlanNCT03615924v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease,23,
421,NCT03616912,Phase 3,Systemic Lupus Erythematosus,0,,Protocol NCT03616899v1.0.doc,Statitical Analysis PlanNCT03616899v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Safety and Efficacy of KPI-121 in Subjects With DED,22,
420,NCT03616964,Phase 3,Systemic Lupus Erythematosus,0,,Protocol NCT03616912v1.0.doc,Statitical Analysis PlanNCT03616912v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus,21,
419,NCT03621280,Phase 3,Cushing Syndrome|Cushing Disease,0,,Protocol NCT03616964v1.0.doc,Statitical Analysis PlanNCT03616964v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study of Baricitinib in Participants With Systemic Lupus Erythematosus,20,
418,NCT03619213,Phase 3,Heart Failure With Preserved Ejection Fraction,0,,Protocol NCT03621280v1.0.doc,Statitical Analysis PlanNCT03621280v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Open-label Treatment in Cushing's Syndrome,19,
417,NCT03623321,Phase 3,Neuropsychiatric Symptoms Related to Neurodegenerative Disease,0,,Protocol NCT03619213v1.0.doc,Statitical Analysis PlanNCT03619213v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.,18,
416,NCT03620162,Phase 3,Pneumococcal Infections,0,,Protocol NCT03623321v1.0.doc,Statitical Analysis PlanNCT03623321v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease,17,
415,NCT03621670,Phase 3,"Infections, Meningococcal",0,,Protocol NCT03620162v1.0.doc,Statitical Analysis PlanNCT03620162v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION),16,
414,NCT03622580,Phase 3,Diabetic Macular Edema,0,,Protocol NCT03621670v1.0.doc,Statitical Analysis PlanNCT03621670v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,GlaxoSmithKline's (GSK) Safety and Immunogenicity Study of GSK Meningococcal Group B and 13-valent Pneumococcal Vaccines Administered Together With Routine Infant Vaccines in Healthy Infants,15,
413,NCT03622593,Phase 3,Diabetic Macular Edema,0,,Protocol NCT03622580v1.0.doc,Statitical Analysis PlanNCT03622580v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE),14,
412,NCT03624127,Phase 3,Psoriasis,0,,Protocol NCT03622593v1.0.doc,Statitical Analysis PlanNCT03622593v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema,13,
411,NCT03627468,Phase 3,Primary Axillary Hyperhidrosis,0,,Protocol NCT03624127v1.0.doc,Statitical Analysis PlanNCT03624127v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate to Severe Plaque Psoriasis,12,
410,NCT03627091,Phase 3,Crohn's Disease,0,,Protocol NCT03627468v1.0.doc,Statitical Analysis PlanNCT03627468v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis,11,
409,NCT03627767,Phase 3,"Dermatitis|Dermatitis, Atopic|Eczema|Skin Diseases|Skin Diseases, Genetic|Genetic Diseases, Inborn|Skin Diseases, Eczematous|Hypersensitivity|Hypersensitivity, Immediate|Immune System Diseases",0,,Protocol NCT03627091v1.0.doc,Statitical Analysis PlanNCT03627091v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307),10,
408,NCT03630952,Phase 3,Neovascular Age-related Macular Degeneration,1,,Protocol NCT03627767v1.0.doc,Statitical Analysis PlanNCT03627767v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects,9,
407,NCT03629184,Phase 3,Influenza,0,,Protocol NCT03630952v1.0.doc,Statitical Analysis PlanNCT03630952v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration (PANDA-2),8,
406,NCT03631732,Phase 3,HIV-1 Infection,0,,Protocol NCT03629184v1.0.doc,Statitical Analysis PlanNCT03629184v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms",7,
405,NCT03633799,Phase 3,Women at Risk for Pregnancy,0,,Protocol NCT03631732v1.0.doc,Statitical Analysis PlanNCT03631732v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants",6,
404,NCT03635788,Phase 3,HIV Infections,0,,Protocol NCT03633799v1.0.doc,Statitical Analysis PlanNCT03633799v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"Evaluation of Efficacy, Safety and Tolerability of VeraCept IUD",5,
403,NCT03635983,Phase 3,Melanoma,0,,Protocol NCT03635788v1.0.doc,Statitical Analysis PlanNCT03635788v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Evaluating Long-Acting Antiretroviral Therapy in Non-Adherent HIV-Infected Individuals,4,
402,NCT03721016,Phase 3,"Glabellar Lines, Lateral Canthal Lines",1,,Protocol NCT03635983v1.0.doc,Statitical Analysis PlanNCT03635983v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma,3,
401,NCT03642132,Phase 3,Ovarian Cancer,0,,Protocol NCT03721016v1.0.doc,Statitical Analysis PlanNCT03721016v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,MT10109L in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines,2,
400,NCT03727100,Phase 3,Lumbosacral Radiculopathy,0,,Protocol NCT03642132v1.0.doc,Statitical Analysis PlanNCT03642132v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100),1,
399,NCT03728738,Phase 3,Ischemic Stroke,0,,Protocol NCT03727100v1.0.doc,Statitical Analysis PlanNCT03727100v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Treatment of Pain Associated With Lumbosacral Radiculopathy in Adults,100,
398,NCT03652064,Phase 3,Multiple Myeloma,0,,Protocol NCT03728738v1.0.doc,Statitical Analysis PlanNCT03728738v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke,99,
397,NCT03653364,Phase 3,Influenza,0,,Protocol NCT03652064v1.0.doc,Statitical Analysis PlanNCT03652064v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy",98,
396,NCT03732833,Phase 3,"Lateral Canthal Lines, Glabellar Lines",0,,Protocol NCT03653364v1.0.doc,Statitical Analysis PlanNCT03653364v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms",97,
395,NCT03653026,Phase 3,Ulcerative Colitis (UC),1,,Protocol NCT03732833v1.0.doc,Statitical Analysis PlanNCT03732833v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines,96,
394,NCT03654729,Phase 3,Chemotherapy-induced Peripheral Neuropathy,0,,Protocol NCT03653026v1.0.doc,Statitical Analysis PlanNCT03653026v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis,95,
393,NCT03739203,Phase 3,Major Depressive Disorder,0,,Protocol NCT03654729v1.0.doc,Statitical Analysis PlanNCT03654729v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M),94,
392,NCT03659929,Phase 3,Attention Deficit Hyperactivity Disorder,0,,Protocol NCT03739203v1.0.doc,Statitical Analysis PlanNCT03739203v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"The Object of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone",93,
391,NCT03660943,Phase 3,"Osteoarthritis, Knee",0,,Protocol NCT03659929v1.0.doc,Statitical Analysis PlanNCT03659929v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate,92,
390,NCT03661320,Phase 3,Bladder Cancer|Muscle-Invasive Bladder Cancer|BMS-986205,0,,Protocol NCT03660943v1.0.doc,Statitical Analysis PlanNCT03660943v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain,91,
389,NCT03664674,Phase 3,Meniere Disease,0,,Protocol NCT03661320v1.0.doc,Statitical Analysis PlanNCT03661320v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC",90,
388,NCT03665038,Phase 3,Post Partum Depression,1,,Protocol NCT03664674v1.0.doc,Statitical Analysis PlanNCT03664674v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease,89,
387,NCT03668600,Phase 3,"Depressive Disorder, Major",0,,Protocol NCT03665038v1.0.doc,Statitical Analysis PlanNCT03665038v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study to Assess the Safety and Efficacy of Brexanolone in the Treatment of Adolescent Female Subjects With Postpartum Depression,88,
386,NCT03673462,Phase 3,Healthy Volunteers (Meningococcal Infection),0,,Protocol NCT03668600v1.0.doc,Statitical Analysis PlanNCT03668600v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD),87,
385,NCT03677934,Phase 3,Neovascular Age-Related Macular Degeneration,1,,Protocol NCT03673462v1.0.doc,Statitical Analysis PlanNCT03673462v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers,86,
384,NCT03679884,Phase 3,Insomnia Disorder,0,,Protocol NCT03677934v1.0.doc,Statitical Analysis PlanNCT03677934v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Phase III Study to Evaluate the Port Delivery System Implant With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway),85,
383,NCT03682068,Phase 3,Unresectable Locally Advanced Urothelial Cancer|Metastatic Urothelial Cancer,0,,Protocol NCT03679884v1.0.doc,Statitical Analysis PlanNCT03679884v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep,84,
382,NCT03682536,Phase 3,Myelodysplastic Syndromes,0,,Protocol NCT03682068v1.0.doc,Statitical Analysis PlanNCT03682068v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer",83,
381,NCT03683251,Phase 3,Neovascular Age-Related Macular Degeneration,0,,Protocol NCT03682536v1.0.doc,Statitical Analysis PlanNCT03682536v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions",82,
380,NCT03684044,Phase 3,Influenza,0,,Protocol NCT03683251v1.0.doc,Statitical Analysis PlanNCT03683251v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Extension Study for the Port Delivery System With Ranibizumab (Portal),81,
379,NCT03686215,Phase 3,Breast Cancer,0,,Protocol NCT03684044v1.0.doc,Statitical Analysis PlanNCT03684044v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza,80,
378,NCT03690206,Phase 3,Short Bowel Syndrome,0,,Protocol NCT03686215v1.0.doc,Statitical Analysis PlanNCT03686215v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Pivotal Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients,79,
377,NCT03687372,Phase 3,Common Wart,0,,Protocol NCT03690206v1.0.doc,Statitical Analysis PlanNCT03690206v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS,78,
376,NCT03694522,Phase 3,Gastric Cancer,1,,Protocol NCT03687372v1.0.doc,Statitical Analysis PlanNCT03687372v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study of A-101 Topical Solution for the Treatment of Common Warts,77,
375,NCT03691610,Phase 3,Healthy Volunteers (Meningococcal Infection),0,,Protocol NCT03694522v1.0.doc,Statitical Analysis PlanNCT03694522v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT),76,
374,NCT03691649,Phase 3,Glaucoma and Ocular Hypertension,0,,Protocol NCT03691610v1.0.doc,Statitical Analysis PlanNCT03691610v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers,75,
373,NCT03691662,Phase 3,Glaucoma and Ocular Hypertension,0,,Protocol NCT03691649v1.0.doc,Statitical Analysis PlanNCT03691649v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study,74,
372,NCT03691831,Phase 3,Common Wart,0,,Protocol NCT03691662v1.0.doc,Statitical Analysis PlanNCT03691662v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study,73,
371,NCT03693430,Phase 3,Overweight|Obesity,0,,Protocol NCT03691831v1.0.doc,Statitical Analysis PlanNCT03691831v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study of A-101 Topical Solution for the Treatment of Common Warts,72,
370,NCT03695237,Phase 3,Central Precocious Puberty (CPP),0,,Protocol NCT03693430v1.0.doc,Statitical Analysis PlanNCT03693430v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity,71,
369,NCT03697811,Phase 3,Primary Open-angle Glaucoma,0,,Protocol NCT03695237v1.0.doc,Statitical Analysis PlanNCT03695237v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)",70,
368,NCT03726879,Phase 3,Breast Cancer,0,,Protocol NCT03697811v1.0.doc,Statitical Analysis PlanNCT03697811v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,DE-117 Spectrum 5 Study,69,
367,NCT03700320,Phase 3,Episodic Migraine,0,,Protocol NCT03726879v1.0.doc,Statitical Analysis PlanNCT03726879v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer,68,
366,NCT03703297,Phase 3,Small Cell Lung Cancer,0,,Protocol NCT03700320v1.0.doc,Statitical Analysis PlanNCT03700320v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine,67,
365,NCT03701399,Phase 3,Spinocerebellar Ataxias|Spinocerebellar Ataxia Type 1|Spinocerebellar Ataxia Type 2|Spinocerebellar Ataxia Type 3|Spinocerebellar Ataxia Type 6|Spinocerebellar Ataxia Type 7|Spinocerebellar Ataxia Type 8|Spinocerebellar Ataxia Type 10,0,,Protocol NCT03703297v1.0.doc,Statitical Analysis PlanNCT03703297v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy",66,
364,NCT03712137,Phase 3,Jawline Definition,0,,Protocol NCT03701399v1.0.doc,Statitical Analysis PlanNCT03701399v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,BHV-4157 in Adult Subjects With Spinocerebellar Ataxia,65,
363,NCT03712605,Phase 3,Pathologic Stage I Merkel Cell Carcinoma AJCC v8|Pathologic Stage II Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8|Pathologic Stage III Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8|Resected Mass,0,,Protocol NCT03712137v1.0.doc,Statitical Analysis PlanNCT03712137v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition,64,
362,NCT03747458,Phase 3,Bilateral Nasal Polyposis,0,,Protocol NCT03712605v1.0.doc,Statitical Analysis PlanNCT03712605v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer,63,
361,NCT03717506,Phase 3,Acne Vulgaris,0,,Protocol NCT03747458v1.0.doc,Statitical Analysis PlanNCT03747458v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps,62,
360,NCT03725202,Phase 3,Giant Cell Arteritis (GCA),0,,Protocol NCT03717506v1.0.doc,Statitical Analysis PlanNCT03717506v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris",61,
359,NCT03730662,Phase 3,Type 2 Diabetes Mellitus,0,,Protocol NCT03725202v1.0.doc,Statitical Analysis PlanNCT03725202v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis,60,
358,NCT03737214,Phase 3,Fabry Disease,0,,Protocol NCT03730662v1.0.doc,Statitical Analysis PlanNCT03730662v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk,59,
357,NCT03731091,Phase 3,Psoriasis Vulgaris,0,,Protocol NCT03737214v1.0.doc,Statitical Analysis PlanNCT03737214v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease,58,
356,NCT03732677,Phase 3,Muscle Invasive Bladder Cancer,0,,Protocol NCT03731091v1.0.doc,Statitical Analysis PlanNCT03731091v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).",57,
355,NCT03732820,Phase 3,Metastatic Castration-resistant Prostate Cancer,0,,Protocol NCT03732677v1.0.doc,Statitical Analysis PlanNCT03732677v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC,56,
354,NCT03737643,Phase 3,Advanced Ovarian Cancer,0,,Protocol NCT03732820v1.0.doc,Statitical Analysis PlanNCT03732820v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer,55,
353,NCT03738618,Phase 3,"Infertility, Female",0,,Protocol NCT03737643v1.0.doc,Statitical Analysis PlanNCT03737643v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.",54,
352,NCT03739112,Phase 3,Virus Diseases|RNA Virus Infections|Respiratory Tract Diseases|Respiratory Tract Infections,1,,Protocol NCT03738618v1.0.doc,Statitical Analysis PlanNCT03738618v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2),53,
351,NCT03739684,Phase 3,Prostate Cancer|Prostate Adenocarcinoma|Prostate Cancer Recurrent|Prostate Cancer Metastatic,0,,Protocol NCT03739112v1.0.doc,Statitical Analysis PlanNCT03739112v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Efficacy of a Plant-derived Quadrivalent VLP Vaccine in the Elderly,52,
350,NCT03740737,Phase 3,Infertility,0,,Protocol NCT03739684v1.0.doc,Statitical Analysis PlanNCT03739684v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer,51,
349,NCT03745651,Phase 3,Atopic Dermatitis,0,,Protocol NCT03740737v1.0.doc,Statitical Analysis PlanNCT03740737v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1),50,
348,NCT03745638,Phase 3,Atopic Dermatitis,0,,Protocol NCT03745651v1.0.doc,Statitical Analysis PlanNCT03745651v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis,49,
347,NCT03406507,Phase 3,Paroxysmal Nocturnal Hemoglobinuria (PNH),0,,Protocol NCT03745638v1.0.doc,Statitical Analysis PlanNCT03745638v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis,48,
346,NCT03653507,Phase 3,Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer|Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer|Metastatic Gastric Adenocarcinoma or Cancer|Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma,0,,Protocol NCT03406507v1.0.doc,Statitical Analysis PlanNCT03406507v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH)",47,
345,NCT03160547,Phase 3,Critical Illness|Malnutrition,0,,Protocol NCT03653507v1.0.doc,Statitical Analysis PlanNCT03653507v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",46,
344,NCT03532542,Phase 3,Duchenne Muscular Dystrophy,0,,Protocol NCT03160547v1.0.doc,Statitical Analysis PlanNCT03160547v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,The Effect of Higher Protein Dosing in Critically Ill Patients,45,
343,NCT03738397,Phase 3,Atopic Dermatitis,0,,Protocol NCT03532542v1.0.doc,Statitical Analysis PlanNCT03532542v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy,44,
342,NCT03439072,Phase 3,Insulin Hypoglycemia|Type 1 Diabetes Mellitus|Severe Hypoglycemia,0,,Protocol NCT03738397v1.0.doc,Statitical Analysis PlanNCT03738397v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis,43,
341,NCT03428360,Phase 3,Epilepsy,0,,Protocol NCT03439072v1.0.doc,Statitical Analysis PlanNCT03439072v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes,42,
340,NCT03434275,Phase 3,"Pain, Postoperative",0,,Protocol NCT03428360v1.0.doc,Statitical Analysis PlanNCT03428360v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Safety and Tolerability Study of Diazepam Buccal Soluble Film (DBSF) in Subjects With Epilepsy,41,
339,NCT03479307,Phase 3,Allergic Conjunctivitis,0,,Protocol NCT03434275v1.0.doc,Statitical Analysis PlanNCT03434275v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Evaluation of Preoperative N1539 in Total Knee Arthroplasty,40,
338,NCT03545607,Phase 3,Ischemic Stroke,0,,Protocol NCT03479307v1.0.doc,Statitical Analysis PlanNCT03479307v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model,39,
337,NCT03632135,Phase 3,Recurrent Glioblastoma,0,,Protocol NCT03545607v1.0.doc,Statitical Analysis PlanNCT03545607v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study,38,
336,NCT03686683,Phase 3,Adenocarcinoma of the Prostate,0,,Protocol NCT03632135v1.0.doc,Statitical Analysis PlanNCT03632135v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma,37,
335,NCT03691779,Phase 3,Cystic Fibrosis,0,,Protocol NCT03686683v1.0.doc,Statitical Analysis PlanNCT03686683v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer,36,
334,NCT03710564,Phase 3,Age-Related Macular Degeneration,0,,Protocol NCT03691779v1.0.doc,Statitical Analysis PlanNCT03691779v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age,35,
333,NCT03721705,Phase 3,"Alzheimer Disease|Cognitive Dysfunction|Mild Cognitive Impairment|Mild Dementia|Cognitive Decline|Dementia, Alzheimer Type",0,,Protocol NCT03710564v1.0.doc,Statitical Analysis PlanNCT03710564v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections,34,
332,NCT03409744,Phase 3,Homozygous Familial Hypercholesterolemia,0,,Protocol NCT03721705v1.0.doc,Statitical Analysis PlanNCT03721705v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due AD or Mild Dementia of the Alzheimer's Type,33,
331,NCT03433677,Phase 3,Diabetes Type 1,1,,Protocol NCT03409744v1.0.doc,Statitical Analysis PlanNCT03409744v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia,32,
330,NCT03180307,Phase 3,Ovarian Cancer,0,,Protocol NCT03433677v1.0.doc,Statitical Analysis PlanNCT03433677v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes,31,
329,NCT03250338,Phase 3,Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations,0,,Protocol NCT03180307v1.0.doc,Statitical Analysis PlanNCT03180307v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer,30,
328,NCT03421496,Phase 3,Infantile Spasm,0,,Protocol NCT03250338v1.0.doc,Statitical Analysis PlanNCT03250338v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML,29,
327,NCT03567057,Phase 3,Multiple Sclerosis|Walking Impairment,0,,Protocol NCT03421496v1.0.doc,Statitical Analysis PlanNCT03421496v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"A Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms",28,
326,NCT03610048,Phase 3,Refractory Major Depressive Disorder,0,,Protocol NCT03567057v1.0.doc,Statitical Analysis PlanNCT03567057v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment,27,
325,NCT03626688,Phase 3,"PAH|Pulmonary Hypertension|Pulmonary Arterial Hypertension|Hypertension|Connective Tissue Diseases|Familial Primary Pulmonary Hypertension|Vascular Diseases|Cardiovascular Diseases|Hypertension, Pulmonary|Lung Diseases|Respiratory Tract Disease",1,,Protocol NCT03610048v1.0.doc,Statitical Analysis PlanNCT03610048v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD),26,
324,NCT03670953,Phase 3,Parkinson's Disease (Disorder),0,,Protocol NCT03626688v1.0.doc,Statitical Analysis PlanNCT03626688v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients,25,
323,NCT03684642,Phase 3,Type 2 Diabetes Mellitus,0,,Protocol NCT03670953v1.0.doc,Statitical Analysis PlanNCT03670953v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor Fluctuations,24,
322,NCT03711929,Phase 3,Non Infectious Uveitis,0,,Protocol NCT03684642v1.0.doc,Statitical Analysis PlanNCT03684642v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin,23,
321,NCT03738215,Phase 3,Major Depressive Disorder,0,,Protocol NCT03711929v1.0.doc,Statitical Analysis PlanNCT03711929v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"A Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye",22,
320,NCT03602781,Phase 3,Pulmonary Arterial Hypertension,0,,Protocol NCT03738215v1.0.doc,Statitical Analysis PlanNCT03738215v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone",21,
319,NCT03539952,Phase 3,Wilson Disease,0,,Protocol NCT03602781v1.0.doc,Statitical Analysis PlanNCT03602781v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric,20,
318,NCT03729245,Phase 3,Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma,1,,Protocol NCT03539952v1.0.doc,Statitical Analysis PlanNCT03539952v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease,19,
317,NCT03040778,Phase 3,Medication-related Osteonecrosis of the Jaw|Bisphosphonate-related Osteonecrosis of the Jaw|Avascular Necrosis,0,,Protocol NCT03729245v1.0.doc,Statitical Analysis PlanNCT03729245v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC),18,
316,NCT03357614,Phase 3,Complicated Urinary Tract Infections,0,,Protocol NCT03040778v1.0.doc,Statitical Analysis PlanNCT03040778v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ),17,
315,NCT03364738,Phase 3,Hypoparathyroidism,0,,Protocol NCT03357614v1.0.doc,Statitical Analysis PlanNCT03357614v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults,16,
314,NCT03467958,Phase 3,Crohn Disease,0,,Protocol NCT03364738v1.0.doc,Statitical Analysis PlanNCT03364738v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism,15,
313,NCT03547206,Phase 3,Nonarteritic Anterior Ischemic Optic Neuropathy,0,,Protocol NCT03467958v1.0.doc,Statitical Analysis PlanNCT03467958v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease,14,
312,NCT03589326,Phase 3,"Lymphoblastic Leukemia, Acute, Adult|Acute Lymphoid Leukemia|Leukemia, Acute Lymphoblastic|Leukemia, Lymphoblastic|Ph1 Chromosome|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive",0,,Protocol NCT03547206v1.0.doc,Statitical Analysis PlanNCT03547206v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION),13,
311,NCT03596723,Phase 3,Ocular Inflammation,1,,Protocol NCT03589326v1.0.doc,Statitical Analysis PlanNCT03589326v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,"An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)",12,
310,NCT03600805,Phase 3,Giant Cell Arteritis,0,,Protocol NCT03596723v1.0.doc,Statitical Analysis PlanNCT03596723v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children,11,
309,NCT03616470,Phase 3,Acute Myeloid Leukemia,0,,Protocol NCT03600805v1.0.doc,Statitical Analysis PlanNCT03600805v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA,10,
308,NCT03618030,Phase 3,ADHD,1,,Protocol NCT03616470v1.0.doc,Statitical Analysis PlanNCT03616470v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia,9,
307,NCT03633617,Phase 3,Eosinophilic Esophagitis,0,,Protocol NCT03618030v1.0.doc,Statitical Analysis PlanNCT03618030v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,PRC-063 Adult Laboratory Classroom Study in Adults With ADHD,8,
306,NCT03636269,Phase 3,Uremic Pruritus,0,,Protocol NCT03633617v1.0.doc,Statitical Analysis PlanNCT03633617v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE),7,
305,NCT03703882,Phase 3,"Muscular Dystrophy, Duchenne",0,,Protocol NCT03636269v1.0.doc,Statitical Analysis PlanNCT03636269v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus,6,
304,NCT03734016,Phase 3,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,0,,Protocol NCT03703882v1.0.doc,Statitical Analysis PlanNCT03703882v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy,5,
303,NCT03672487,Phase 3,Chagas Disease,0,,Protocol NCT03734016v1.0.doc,Statitical Analysis PlanNCT03734016v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia,4,
302,NCT03149809,Phase 3,Overactive Bladder|Parkinson Disease,0,,Protocol NCT03672487v1.0.doc,Statitical Analysis PlanNCT03672487v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age,3,
301,NCT03272685,Phase 3,Tobacco Smoking|Nicotine Dependence,0,,Protocol NCT03149809v1.0.doc,Statitical Analysis PlanNCT03149809v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease,2,
300,NCT03290131,Phase 3,"Multiple Sclerosis|Spasticity, Muscle",0,,Protocol NCT03272685v1.0.doc,Statitical Analysis PlanNCT03272685v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace,1,
299,NCT03341156,Phase 3,Heart Disease End Stage|Heart Failure，Congestive,1,,Protocol NCT03290131v1.0.doc,Statitical Analysis PlanNCT03290131v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS,100,
298,NCT03434678,Phase 3,Pancreatic Cancer,0,,Protocol NCT03341156v1.0.doc,Statitical Analysis PlanNCT03341156v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation,99,
297,NCT03486938,Phase 3,Mild Cognitive Impairment|Prodromal Alzheimer's Disease,0,,Protocol NCT03434678v1.0.doc,Statitical Analysis PlanNCT03434678v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection,98,
296,NCT03531255,Phase 3,PNH,0,,Protocol NCT03486938v1.0.doc,Statitical Analysis PlanNCT03486938v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease,97,
295,NCT03572933,Phase 3,CDKL5 Deficiency Disorder,0,,Protocol NCT03531255v1.0.doc,Statitical Analysis PlanNCT03531255v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Multi-center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH),96,
294,NCT03579758,Phase 3,Stage I Gallbladder Cancer AJCC v8|Stage II Gallbladder Cancer AJCC v8|Stage IIA Gallbladder Cancer AJCC v8|Stage IIB Gallbladder Cancer AJCC v8|Stage III Gallbladder Cancer AJCC v8|Stage IIIA Gallbladder Cancer AJCC v8|Stage IIIB Gallbladder Cancer AJCC v8,0,,Protocol NCT03572933v1.0.doc,Statitical Analysis PlanNCT03572933v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder,95,
293,NCT03581123,Phase 3,"Acute Pain|Low Back Pain, Mechanical",0,,Protocol NCT03579758v1.0.doc,Statitical Analysis PlanNCT03579758v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer,94,
292,NCT03606460,Phase 3,Multiple Sclerosis,0,,Protocol NCT03581123v1.0.doc,Statitical Analysis PlanNCT03581123v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain,93,
291,NCT03632798,Phase 3,Recurrent Ovarian Cancer,0,,Protocol NCT03606460v1.0.doc,Statitical Analysis PlanNCT03606460v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS),92,
290,NCT03647267,Phase 3,Vitreomacular Traction,0,,Protocol NCT03632798v1.0.doc,Statitical Analysis PlanNCT03632798v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer,91,
289,NCT03649659,Phase 3,Cavities of Teeth,0,,Protocol NCT03647267v1.0.doc,Statitical Analysis PlanNCT03647267v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Effects of Pneumatic Vitreolysis on Vitreomacular Traction,90,
288,NCT03688711,Phase 3,"Hypoglycemia|Diabetes Mellitus, Type 1",0,,Protocol NCT03649659v1.0.doc,Statitical Analysis PlanNCT03649659v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Effectiveness of Silver Diamine Fluoride (SDF) in Arresting Cavitated Caries Lesions,89,
287,NCT03711162,Phase 3,Idiopathic Pulmonary Fibrosis,0,,Protocol NCT03688711v1.0.doc,Statitical Analysis PlanNCT03688711v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM,88,
286,NCT03720470,Phase 3,"Dermatitis|Dermatitis, Atopic|Eczema|Skin Diseases|Skin Diseases, Genetic|Genetic Diseases, Inborn|Skin Diseases, Eczematous|Hypersensitivity|Hypersensitivity, Immediate|Immune System Diseases",0,,Protocol NCT03711162v1.0.doc,Statitical Analysis PlanNCT03711162v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard Medical Treatment,87,
285,NCT03523962,Phase 3,Surgical Site Infection|Unplanned Fracture-Related Reoperation|Open Fracture|Lower Extremity Fracture|Pelvis,0,,Protocol NCT03720470v1.0.doc,Statitical Analysis PlanNCT03720470v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy,86,
284,NCT03620747,Phase 3,Asthma, Fracture,0,,Protocol NCT03523962v1.0.doc,Statitical Analysis PlanNCT03523962v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Pre-operative Alcohol Skin Solutions in Fractured Extremities,85
283,NCT03007420,Phase 3,Post-Traumatic Headaches,0,,Protocol NCT03620747v1.0.doc,Statitical Analysis PlanNCT03620747v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up),84,
282,NCT03358576,Phase 3,Intra Abdominal Infections,0,,Protocol NCT03007420v1.0.doc,Statitical Analysis PlanNCT03007420v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,A Prospective Controlled Treatment Trial for Post-Traumatic Headaches,83,
281,NCT03404518,Phase 3,"Outpatient Surgery|Pain, Postoperative",0,,Protocol NCT03358576v1.0.doc,Statitical Analysis PlanNCT03358576v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI),82,
280,NCT03410524,Phase 3,Colonoscopy,0,,Protocol NCT03404518v1.0.doc,Statitical Analysis PlanNCT03404518v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Patient Narcotic Requirements After Outpatient Otolaryngology Procedures,81,
279,NCT03417687,Phase 3,Pulmonary Surgical Procedures,0,,Protocol NCT03410524v1.0.doc,Statitical Analysis PlanNCT03410524v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Evaluation of Oral Simethicone With Low Volume Polyethylene Glycol Bowel Preparation During Colonoscopy,80,
278,NCT03418090,Phase 3,Pulmonary Surgical Procedures,0,,Protocol NCT03417687v1.0.doc,Statitical Analysis PlanNCT03417687v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection,79,
277,NCT03422198,Phase 3,Endometrial Clear Cell Adenocarcinoma|Endometrial Endometrioid Adenocarcinoma|Endometrial Serous Adenocarcinoma|Stage I Uterine Corpus Cancer|Stage IA Uterine Corpus Cancer|Stage IB Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Uterine Corpus Carcinosarcoma|Uterine Corpus Sarcoma,0,,Protocol NCT03418090v1.0.doc,Statitical Analysis PlanNCT03418090v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Transplant,78,
276,NCT03445650,Phase 3,Sjogren-Larsson Syndrome,0,,Protocol NCT03422198v1.0.doc,Statitical Analysis PlanNCT03422198v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer,77,
275,NCT03480009,Phase 3,Abortion in First Trimester,1,,Protocol NCT03445650v1.0.doc,Statitical Analysis PlanNCT03445650v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,RESET Trial - Part 1 (Followed by Reset Trial - Part 2) - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS),76,
274,NCT03504410,Phase 3,Relapsed/Refractory Acute Myeloid Leukemia,0,,Protocol NCT03480009v1.0.doc,Statitical Analysis PlanNCT03480009v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion,75,
273,NCT03535675,Phase 3,Adenocarcinoma of the Prostate,0,,Protocol NCT03504410v1.0.doc,Statitical Analysis PlanNCT03504410v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Phase III Randomized Trial of 500 Patients With Relapsed/Refractory Acute Myeloid Leukemia,74,
272,NCT03573882,Phase 3,Sickle Cell Disease,0,,Protocol NCT03535675v1.0.doc,Statitical Analysis PlanNCT03535675v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Muscadine Plus (MPX) In Men With Prostate Cancer,73,
271,NCT03584373,Phase 3,Nephrolithiasis,0,,Protocol NCT03573882v1.0.doc,Statitical Analysis PlanNCT03573882v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Study to Assess the Effect of Long-term Treatment With GBT440 in Participants Who Have Completed Treatment in Study GBT440-031,72,
270,NCT03591068,Phase 3,Bilateral Nasal Polyposis,0,,Protocol NCT03584373v1.0.doc,Statitical Analysis PlanNCT03584373v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Pain Outcomes of Non-opioid vs. Opioid Analgesia for Kidney Stone Surgery.,71,
269,NCT03633526,Phase 3,Cystic Fibrosis,0,,Protocol NCT03591068v1.0.doc,Statitical Analysis PlanNCT03591068v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video,70,
268,NCT03636451,Phase 3,"Abortion, Spontaneous|Abortion in First Trimester|Pain Uterus",0,,Protocol NCT03633526v1.0.doc,Statitical Analysis PlanNCT03633526v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age,69,
267,NCT03640325,Phase 3,"Cancer|Bone Marrow Neoplasms|Anxiety|Depression|Quality of Life|Adherence, Medication|Coping Skills|Adolescent Behavior",0,,Protocol NCT03636451v1.0.doc,Statitical Analysis PlanNCT03636451v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Paracervical Block Volume and Pain Control During Dilation and Curettage,68,
266,NCT03649477,Phase 3,Prader-Willi Syndrome,0,,Protocol NCT03640325v1.0.doc,Statitical Analysis PlanNCT03640325v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,The Promoting Resilience in Stress Management (PRISM) Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation,67,
265,NCT03649711,Phase 3,"Chronic Kidney Diseases|Heart Attack|Stroke, Ischemic",0,,Protocol NCT03649477v1.0.doc,Statitical Analysis PlanNCT03649477v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome,66,
264,NCT03651752,Phase 3,Alopecia Areata,0,,Protocol NCT03649711v1.0.doc,Statitical Analysis PlanNCT03649711v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,Chronic Kidney Disease (CKD) Platelet Study,65,
263,NCT03654274,Phase 3,Endometriosis,0,,Protocol NCT03651752v1.0.doc,Statitical Analysis PlanNCT03651752v1.0.doc,2019-04-06 00:26:42,2019-04-06 00:26:42,DPCP for the Treatment of Alopecia Areata,64,
262,NCT03656783,Phase 3,HIV,0,,Protocol NCT03654274v1.0.doc,Statitical Analysis PlanNCT03654274v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain,63,
261,NCT03656874,Phase 3,Smoking,0,,Protocol NCT03656783v1.0.doc,Statitical Analysis PlanNCT03656783v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Effects of Biktarvy on CFR in Stable HIV Patients,62,
260,NCT03697109,Phase 3,Cushing Syndrome,0,,Protocol NCT03656874v1.0.doc,Statitical Analysis PlanNCT03656874v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Engaging Patients in Tobacco Cessation Resources in Dental Settings,61,
259,NCT03710291,Phase 3,Metabolic Acidosis|Chronic Kidney Disease,0,,Protocol NCT03697109v1.0.doc,Statitical Analysis PlanNCT03697109v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Study of the Efficacy and Safety of Relacorilant,60,
258,NCT03715491,Phase 3,Tobacco Use,0,,Protocol NCT03710291v1.0.doc,Statitical Analysis PlanNCT03710291v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis,59,
257,NCT03730480,Phase 3,Diabetes Mellitus,0,,Protocol NCT03715491v1.0.doc,Statitical Analysis PlanNCT03715491v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Filter Ventilation,58,
256,NCT03731052,Phase 3,Plaque Psoriasis,0,,Protocol NCT03730480v1.0.doc,Statitical Analysis PlanNCT03730480v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS),57,
255,NCT03737240,Phase 3,Diabetes Mellitus,0,,Protocol NCT03731052v1.0.doc,Statitical Analysis PlanNCT03731052v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307),56,
254,NCT03750227,Phase 3,Metastatic Malignant Neoplasm in the Brain|Solid Neoplasm,1,,Protocol NCT03737240v1.0.doc,Statitical Analysis PlanNCT03737240v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,IDegLira HIGH Trial,55,
253,NCT03751098,Phase 3,Mydriasis,0,,Protocol NCT03750227v1.0.doc,Statitical Analysis PlanNCT03750227v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors,54,
252,NCT01543490,Phase 3,"Active, Symptomatic Blepharitis",0,,Protocol NCT03751098v1.0.doc,Statitical Analysis PlanNCT03751098v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation,53,
251,NCT02066649,Phase 3,Portal Hypertension Related to Cirrhosis,0,,Protocol NCT01543490v1.0.doc,Statitical Analysis PlanNCT01543490v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects,52,
250,NCT02329756,Phase 3,Placenta Accreta,0,,Protocol NCT02066649v1.0.doc,Statitical Analysis PlanNCT02066649v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Carvedilol vs Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding,51,
249,NCT02438852,Phase 3,Bladder Carcinoma|Post-operative Pain,0,,Protocol NCT02329756v1.0.doc,Statitical Analysis PlanNCT02329756v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Tranexamic Acid in Adherent Placenta (TAP),50,
248,NCT02588248,Phase 3,Colonic Polyps|Colon Cancer,1,,Protocol NCT02438852v1.0.doc,Statitical Analysis PlanNCT02438852v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer,49,
247,NCT02597465,Phase 3,Advanced Biliary Tract Cancer,0,,Protocol NCT02588248v1.0.doc,Statitical Analysis PlanNCT02588248v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,L-Menthol Infusion as a Novel Technique During Colonoscopy,48,
246,NCT02712151,Phase 3,"Pain, Postoperative",0,,Protocol NCT02597465v1.0.doc,Statitical Analysis PlanNCT02597465v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,"A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507",47,
245,NCT02717728,Phase 3,Hip Surgery Corrective|Anesthesia,0,,Protocol NCT02712151v1.0.doc,Statitical Analysis PlanNCT02712151v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Efficacy of Transversus Abdominis Plane Block for Laparoscopic Cholecystectomy,46,
244,NCT02768467,Phase 3,Tissue Grafts, Functional,0,,Protocol NCT02717728v1.0.doc,Statitical Analysis PlanNCT02717728v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Effectiveness of Fascia Iliaca Nerve Block for Post Hip Arthroscopy,45
243,NCT02793375,Phase 3,Pain,0,,Protocol NCT02768467v1.0.doc,Statitical Analysis PlanNCT02768467v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Buccal Mucosa Healing Trial With Tissue Matrix Placement,44,
242,NCT02929589,Phase 3,Pain|Hernia,0,,Protocol NCT02793375v1.0.doc,Statitical Analysis PlanNCT02793375v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Does Montelukast Decrease Post Adenotonsillectomy Pain in Children,43,
241,NCT02955329,Phase 3,Marijuana Dependence,1,,Protocol NCT02929589v1.0.doc,Statitical Analysis PlanNCT02929589v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy,42,
240,NCT03002571,Phase 3,Atopic Dermatitis,0,,Protocol NCT02955329v1.0.doc,Statitical Analysis PlanNCT02955329v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Vaping THC From Electronic Cigarettes,41,
239,NCT03032432,Phase 3,Rotator Cuff Tendinopathy,0,,Protocol NCT03002571v1.0.doc,Statitical Analysis PlanNCT03002571v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Efficacy and Safety of IDP-124 Lotion,40,
238,NCT03051945,Phase 3,Major Depressive Disorder,0,,Protocol NCT03032432v1.0.doc,Statitical Analysis PlanNCT03032432v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Dynamic Elastic Garment (DEG) in Patients With Rotator Cuff Tendinopathy,39,
237,NCT03058783,Phase 3,Atopic Dermatitis,0,,Protocol NCT03051945v1.0.doc,Statitical Analysis PlanNCT03051945v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Endogenous Opioid Modulation by Ketamine,38,
236,NCT03066466,Phase 3,Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Myelodysplastic Syndrome,0,,Protocol NCT03058783v1.0.doc,Statitical Analysis PlanNCT03058783v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects,37,
235,NCT03173963,Phase 3,Diabetic Kidney Disease|Diabetes Mellitus Type 2,0,,Protocol NCT03066466v1.0.doc,Statitical Analysis PlanNCT03066466v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT,36,
234,NCT03182725,Phase 3,Postural Orthostatic Tachycardia Syndrome,1,,Protocol NCT03173963v1.0.doc,Statitical Analysis PlanNCT03173963v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Empaglifozin in Early Diabetic Kidney Disease,35,
233,NCT03187899,Phase 3,"Pain, Postoperative|Satisfaction",0,,Protocol NCT03182725v1.0.doc,Statitical Analysis PlanNCT03182725v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome,34,
232,NCT03192137,Phase 3,Inflammation and Pain Associated With Cataract Surgery,0,,Protocol NCT03187899v1.0.doc,Statitical Analysis PlanNCT03187899v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Superficial Cervical Plexus Blockade for Clavicle Fracture Analgesia,33,
231,NCT03192150,Phase 3,Inflammation and Pain Associated With Cataract Surgery,1,,Protocol NCT03192137v1.0.doc,Statitical Analysis PlanNCT03192137v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery,32,
230,NCT03203330,Phase 3,Degenerative Osteoarthritis,0,,Protocol NCT03192150v1.0.doc,Statitical Analysis PlanNCT03192150v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Independent Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery,31,
229,NCT03219307,Phase 3,Articular Cartilage Defect,0,,Protocol NCT03203330v1.0.doc,Statitical Analysis PlanNCT03203330v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee,30,
228,NCT03223298,Phase 3,"Pain, Head|Pain Syndrome|Temporomandibular Disorder|Myofascial Pain Syndrome|Myofascial Pain",0,,Protocol NCT03219307v1.0.doc,Statitical Analysis PlanNCT03219307v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,NOVOCART 3D Treatment Following Microfracture Failure,29,
227,NCT03229057,Phase 3,PCOS,0,,Protocol NCT03223298v1.0.doc,Statitical Analysis PlanNCT03223298v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles,28,
226,NCT03246529,Phase 3,Multiple Myeloma,0,,Protocol NCT03229057v1.0.doc,Statitical Analysis PlanNCT03229057v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Comparing the Effects of Oral Contraceptive Pills Versus Metformin,27,
225,NCT03252431,Phase 3,Breast Cancer|Neutropenia,0,,Protocol NCT03246529v1.0.doc,Statitical Analysis PlanNCT03246529v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM",26,
224,NCT03279055,Phase 3,Insomnia,0,,Protocol NCT03252431v1.0.doc,Statitical Analysis PlanNCT03252431v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,25,
223,NCT03282981,Phase 3,Chronic Diabetic Foot Ulcers|Diabetic Neuropathic Ulcers|Non Healing Wound,0,,Protocol NCT03279055v1.0.doc,Statitical Analysis PlanNCT03279055v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Web-based Insomnia Treatment for Adolescent and Young Adult Cancer Survivors,24,
222,NCT03295214,Phase 3,Acetaminophen,1,,Protocol NCT03282981v1.0.doc,Statitical Analysis PlanNCT03282981v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Beta Adrenergic Antagonist for the Healing of Chronic DFU,23,
221,NCT03295981,Phase 3,Giant Cell Tumor of Bone,0,,Protocol NCT03295214v1.0.doc,Statitical Analysis PlanNCT03295214v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Acetaminophen Given Per Os and Intravenous in Sinus Surgery,22,
220,NCT03298958,Phase 3,Bladder Cancer,0,,Protocol NCT03295981v1.0.doc,Statitical Analysis PlanNCT03295981v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone,21,
219,NCT03300609,Phase 3,Colorectal Adenocarcinoma|RAS Wild Type|Stage III Colorectal Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,0,,Protocol NCT03298958v1.0.doc,Statitical Analysis PlanNCT03298958v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer,20,
218,NCT03303677,Phase 3,Chronic Rhinosinusitis (Diagnosis),0,,Protocol NCT03300609v1.0.doc,Statitical Analysis PlanNCT03300609v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab,19,
217,NCT03319732,Phase 3,"Multiple Sclerosis|Spasticity, Muscle",0,,Protocol NCT03303677v1.0.doc,Statitical Analysis PlanNCT03303677v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Comparison of Topical Therapies in Post op Endoscopic Sinus Surgery Patients,18,
216,NCT03327272,Phase 3,Stenosis|Herniated Nucleus Pulposus|Degenerative Disc Disease|Spondylosis|Myelopathy|Radiculopathy|Myeloradiculopathy,0,,Protocol NCT03319732v1.0.doc,Statitical Analysis PlanNCT03319732v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS,17,
215,NCT03331146,Phase 3,Acute Kidney Injury,0,,Protocol NCT03327272v1.0.doc,Statitical Analysis PlanNCT03327272v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Impact of Local Steroid Application in Extreme Lateral Lumbar Interbody Fusion,16,
214,NCT03347526,Phase 3,Infantile Spasm,0,,Protocol NCT03331146v1.0.doc,Statitical Analysis PlanNCT03331146v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Nitrite Infusion in High Risk Patients Undergoing Cardiopulmonary Bypass,15,
213,NCT03350906,Phase 3,Inflammation,0,,Protocol NCT03347526v1.0.doc,Statitical Analysis PlanNCT03347526v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Novel Approach to Infantile Spasms,14,
212,NCT03355768,Phase 3,"Lymphoma, T-Cell, Peripheral",0,,Protocol NCT03350906v1.0.doc,Statitical Analysis PlanNCT03350906v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Enhancing Adaptations to Exercise,13,
211,NCT03367572,Phase 3,Breast Carcinoma,0,,Protocol NCT03355768v1.0.doc,Statitical Analysis PlanNCT03355768v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL,12,
210,NCT03368066,Phase 3,Adrenal Insufficiency|Cirrhosis|Spur Cell Anemia|Lecithin Acyltransferase Deficiency,0,,Protocol NCT03367572v1.0.doc,Statitical Analysis PlanNCT03367572v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer,11,
209,NCT03380143,Phase 3,Physical Activity,0,,Protocol NCT03368066v1.0.doc,Statitical Analysis PlanNCT03368066v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?,10,
208,NCT03386838,Phase 3,Head and Neck Cancer,0,,Protocol NCT03380143v1.0.doc,Statitical Analysis PlanNCT03380143v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Whole-of-Community Systems Intervention for Youth Population Physical Activity,9,
207,NCT03416621,Phase 3,Tobacco Use Cessation,0,,Protocol NCT03386838v1.0.doc,Statitical Analysis PlanNCT03386838v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck,8,
206,NCT03427125,Phase 3,Hyperphosphatemia,0,,Protocol NCT03416621v1.0.doc,Statitical Analysis PlanNCT03416621v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Project Q Pilot: Smoking Cessation for Light Smokers,7,
205,NCT03429400,Phase 3,"Pain, Postoperative",0,,Protocol NCT03427125v1.0.doc,Statitical Analysis PlanNCT03427125v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis,6,
204,NCT03431441,Phase 3,Visual Acuity,0,,Protocol NCT03429400v1.0.doc,Statitical Analysis PlanNCT03429400v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Study of Oral Morphine Sulfate Administration in Pediatric Subjects,5,
203,NCT03432650,Phase 3,Hip Disease,0,,Protocol NCT03431441v1.0.doc,Statitical Analysis PlanNCT03431441v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Clinical Evaluation of 2-Week Reusable ACUVUE 2 Vivid Style,4,
202,NCT03448939,Phase 3,Papulopustular Rosacea,0,,Protocol NCT03432650v1.0.doc,Statitical Analysis PlanNCT03432650v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Evaluation of Anterior Quadratus Lumborum Block for Postoperative Analgesia in Hip Arthroscopy,3,
201,NCT03460470,Phase 3,Heart Failure|Pulmonary Hypertension,0,,Protocol NCT03448939v1.0.doc,Statitical Analysis PlanNCT03448939v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea,2,
200,NCT03466866,Phase 3,Diabetes Mellitus,0,,Protocol NCT03460470v1.0.doc,Statitical Analysis PlanNCT03460470v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Sildenafil in US Heart Failure Patients (SilHF-US),1,
199,NCT03467919,Phase 3,"Osteoarthritis, Knee|Knee Pain",0,,Protocol NCT03466866v1.0.doc,Statitical Analysis PlanNCT03466866v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Reducing Emergency Diabetes Care for Older African Americans,100,
198,NCT03469999,Phase 3,Cerebral Palsy,1,,Protocol NCT03467919v1.0.doc,Statitical Analysis PlanNCT03467919v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Adipose-Derived Stem Cell Injections for Knee Osteoarthritis,99,
197,NCT03480022,Phase 3,Pre Diabetes|Polycystic Ovary Syndrome|Obesity Android,0,,Protocol NCT03469999v1.0.doc,Statitical Analysis PlanNCT03469999v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Dysport on Energy Expenditure,98,
196,NCT03480360,Phase 3,"Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Myelodysplasia|Myeloproliferative Disorder|Myelofibrosis|Lymphoma|Lymphoma, Non-Hodgkin|Plasma Cell Disorder",0,,Protocol NCT03480022v1.0.doc,Statitical Analysis PlanNCT03480022v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,"Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS",97,
195,NCT03480568,Phase 3,Hemodialysis|Peritoneal Dialysis|Hypercholesterolemia|Atherosclerotic Disease,0,,Protocol NCT03480360v1.0.doc,Statitical Analysis PlanNCT03480360v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression,96,
194,NCT03482973,Phase 3,Coronary Artery Disease|Sternal Pain,0,,Protocol NCT03480568v1.0.doc,Statitical Analysis PlanNCT03480568v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Alirocumab in Patients on a Stable Dialysis Regimen,95,
193,NCT03489941,Phase 3,Allergic Conjunctivitis,0,,Protocol NCT03482973v1.0.doc,Statitical Analysis PlanNCT03482973v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Pecto-Intercostal Fascial Block for Postoperative Analgesia After Cardiac Surgery,94,
192,NCT03499873,Phase 3,Cataract,0,,Protocol NCT03489941v1.0.doc,Statitical Analysis PlanNCT03489941v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle,93,
191,NCT03500549,Phase 3,Paroxysmal Nocturnal Hemoglobinuria,0,,Protocol NCT03499873v1.0.doc,Statitical Analysis PlanNCT03499873v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension,92,
190,NCT03504423,Phase 3,Pancreatic Cancer Metastatic,0,,Protocol NCT03500549v1.0.doc,Statitical Analysis PlanNCT03500549v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH,91,
189,NCT03504852,Phase 3,Moderate to Severe Chronic Plaque-type Psoriasis,0,,Protocol NCT03504423v1.0.doc,Statitical Analysis PlanNCT03504423v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Phase III Randomized Trial of 500 Patients With Metastatic Adenocarcinoma of the Pancreas,90,
188,NCT03507803,Phase 3,Ankle Sprains|Ankle Injuries,0,,Protocol NCT03504852v1.0.doc,Statitical Analysis PlanNCT03504852v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Efficacy and Safety of 2 Secukinumab Regimens in 90 kg or Higher Subjects With Moderate to Severe Chronic Plaque-type Psoriasis,89,
187,NCT03508739,Phase 3,"Diabetes Mellitus, Type 2|Pre-diabetic|Hypertension|Elevated Blood Pressure",0,,Protocol NCT03507803v1.0.doc,Statitical Analysis PlanNCT03507803v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Effects of Gait Biofeedback and Impairment-based Rehabilitation in Individuals With Chronic Ankle Instability,88,
186,NCT03512262,Phase 3,"Osteoporosis|Osteoporosis, Age-Related|Osteoporosis Localized to Spine|Age Related Osteoporosis|Osteoporosis Senile|Osteoporosis of Vertebrae",0,,Protocol NCT03508739v1.0.doc,Statitical Analysis PlanNCT03508739v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition,87,
185,NCT03512418,Phase 3,HIV Infections|Substance Use Disorders|Stimulant Use,0,,Protocol NCT03512262v1.0.doc,Statitical Analysis PlanNCT03512262v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM),86,
184,NCT03513068,Phase 3,COPD,0,,Protocol NCT03512418v1.0.doc,Statitical Analysis PlanNCT03512418v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps),85,
183,NCT03513406,Phase 3,Burns,0,,Protocol NCT03513068v1.0.doc,Statitical Analysis PlanNCT03513068v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,"Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)",84,
182,NCT03517358,Phase 3,Hiv,0,,Protocol NCT03513406v1.0.doc,Statitical Analysis PlanNCT03513406v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery,83,
181,NCT03519386,Phase 3,"Glaucoma, Open-Angle|Ocular Hypertension",0,,Protocol NCT03517358v1.0.doc,Statitical Analysis PlanNCT03517358v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Virological Suppression in HIV Positive Patients Involved in a Novel Standardized Adherence Protocol,82,
180,NCT03525873,Phase 3,Metastatic Melanoma,0,,Protocol NCT03519386v1.0.doc,Statitical Analysis PlanNCT03519386v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,"Phase III Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%",81,
179,NCT03526874,Phase 3,"Chronic Migraine, Headache|Episodic Migraine",0,,Protocol NCT03525873v1.0.doc,Statitical Analysis PlanNCT03525873v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Methylphenidate and Physical Activity in Reducing Cancer-Related Fatigue in Participants With Metastatic Melanoma Who Receive Anti-PD1 Immunotherapy,80,
178,NCT03529929,Phase 3,Aging,0,,Protocol NCT03526874v1.0.doc,Statitical Analysis PlanNCT03526874v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Occipital Blocks for Acute Migraine,79,
177,NCT03532022,Phase 3,Congenital Adrenal Hyperplasia,1,,Protocol NCT03529929v1.0.doc,Statitical Analysis PlanNCT03529929v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Glucocorticoid Inflammation Paradox in Human Skeletal Muscle,78,
176,NCT03534284,Phase 3,Insomnia|End Stage Renal Disease,0,,Protocol NCT03532022v1.0.doc,Statitical Analysis PlanNCT03532022v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy,77,
175,NCT03535272,Phase 3,Diarrhea Travelers|Antibiotic Resistant Infection,0,,Protocol NCT03534284v1.0.doc,Statitical Analysis PlanNCT03534284v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis,76,
174,NCT03535402,Phase 3,Rheumatoid Arthritis,0,,Protocol NCT03535272v1.0.doc,Statitical Analysis PlanNCT03535272v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea,75,
173,NCT03536182,Phase 3,Locally Advanced Pancreatic Adenocarcinoma,0,,Protocol NCT03535402v1.0.doc,Statitical Analysis PlanNCT03535402v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics,74,
172,NCT03537534,Phase 3,Dysuria,0,,Protocol NCT03536182v1.0.doc,Statitical Analysis PlanNCT03536182v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,"Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer",73,
171,NCT03537898,Phase 3,"Critical Illness|Acidosis, Metabolic",1,,Protocol NCT03537534v1.0.doc,Statitical Analysis PlanNCT03537534v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Intraurethral Lidocaine After Endourology Procedures,72,
170,NCT03539614,Phase 3,Posttraumatic Stress Disorder,0,,Protocol NCT03537898v1.0.doc,Statitical Analysis PlanNCT03537898v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Balanced Solutions and Plasma Electrolytes,71,
169,NCT03539887,Phase 3,Suicidal Ideation|Depression|Alcohol Abuse,0,,Protocol NCT03539614v1.0.doc,Statitical Analysis PlanNCT03539614v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests,70,
168,NCT03544073,Phase 3,"Infertility|Infertility, Female|Infertility, Male",0,,Protocol NCT03539887v1.0.doc,Statitical Analysis PlanNCT03539887v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse,69,
167,NCT03546491,Phase 3,Dental Plaque,0,,Protocol NCT03544073v1.0.doc,Statitical Analysis PlanNCT03544073v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,GnRH Agonist at Embryo Transfer: IVF Outcomes,68,
166,NCT03549507,Phase 3,Necrotizing Enterocolitis of Newborn|Bowel Ischemic,0,,Protocol NCT03546491v1.0.doc,Statitical Analysis PlanNCT03546491v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Evaluate Dental Plaque Benefit of a Preventive Treatment Gel,67,
165,NCT03549520,Phase 3,Hypoxic-Ischemic Encephalopathy|Brain Ischemia Hypoxia,0,,Protocol NCT03549507v1.0.doc,Statitical Analysis PlanNCT03549507v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis,66,
164,NCT03549897,Phase 3,Asthma,1,,Protocol NCT03549520v1.0.doc,Statitical Analysis PlanNCT03549520v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,CEUS Evaluation of Hypoxic Ischemic Injury,65,
163,NCT03553186,Phase 3,"Spinal Deformity|Degenerative Lumbar Spinal Stenosis|Blood Loss, Surgical",0,,Protocol NCT03549897v1.0.doc,Statitical Analysis PlanNCT03549897v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,"Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base",64,
162,NCT03553498,Phase 3,Acute Pain,0,,Protocol NCT03553186v1.0.doc,Statitical Analysis PlanNCT03553186v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Tranexamic Acid in Adult Spinal Deformity Surgery,63,
161,NCT03553875,Phase 3,Autism|Autism Spectrum Disorder|Nonverbal Learning Disability,0,,Protocol NCT03553498v1.0.doc,Statitical Analysis PlanNCT03553498v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,IV Acetaminophen as Adjuvant Analgesic to Hydromorphone - Emergency Department Patients,62,
160,NCT03554018,Phase 3,Low Back Pain,0,,Protocol NCT03553875v1.0.doc,Statitical Analysis PlanNCT03553875v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions,61,
159,NCT03554265,Phase 3,Traumatic Brain Injury|Fatigue|Cognitive Impairment,0,,Protocol NCT03554018v1.0.doc,Statitical Analysis PlanNCT03554018v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Ibuprofen With or Without Acetaminophen for Low Back Pain,60,
158,NCT03560609,Phase 3,Keratoconus|Glaucoma,0,,Protocol NCT03554265v1.0.doc,Statitical Analysis PlanNCT03554265v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Brain and Gut Plasticity in Mild TBI Following Growth Hormone Therapy,59,
157,NCT03564119,Phase 3,Papulopustular Rosacea,1,,Protocol NCT03560609v1.0.doc,Statitical Analysis PlanNCT03560609v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus,58,
156,NCT03566979,Phase 3,Post-operative Dental Pain,0,,Protocol NCT03564119v1.0.doc,Statitical Analysis PlanNCT03564119v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Study of S5G4T-1 in the Treatment of Papular-Pustular Rosacea,57,
155,NCT03568708,Phase 3,Primary Ovarian Insufficiency,0,,Protocol NCT03566979v1.0.doc,Statitical Analysis PlanNCT03566979v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Efficacy and Safety Study of a Test Naproxen Sodium 220mg Tablet in Postoperative Dental Pain,56,
154,NCT03571672,Phase 3,Cardiac Disease,1,,Protocol NCT03568708v1.0.doc,Statitical Analysis PlanNCT03568708v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Primary Ovarian Insufficiency: Phenotype and Optimal Treatment,55,
153,NCT03571737,Phase 3,Acute Musculoskeletal Disease|Sprains|Sprains and Strains|Injuries|Emergencies|Trauma|Acute Pain,0,,Protocol NCT03571672v1.0.doc,Statitical Analysis PlanNCT03571672v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,DEF-314 Better Accuracy in EF Assessment With DEFINITY,54,
152,NCT03573401,Phase 3,Superficial Basal Cell Carcinoma,0,,Protocol NCT03571737v1.0.doc,Statitical Analysis PlanNCT03571737v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Efficacy of Lidocaine Patch in Acute Musculoskeletal Pain in the Emergency Department,53,
151,NCT03573817,Phase 3,Chronic Obstructive Pulmonary Disease (COPD),0,,Protocol NCT03573401v1.0.doc,Statitical Analysis PlanNCT03573401v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).,52,
150,NCT03574571,Phase 3,Prostate Cancer,0,,Protocol NCT03573817v1.0.doc,Statitical Analysis PlanNCT03573817v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,"A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Subjects With COPD",51,
149,NCT03576820,Phase 3,Migraine,0,,Protocol NCT03574571v1.0.doc,Statitical Analysis PlanNCT03574571v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer,50,
148,NCT03578081,Phase 3,Malignant Neoplasm,0,,Protocol NCT03576820v1.0.doc,Statitical Analysis PlanNCT03576820v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department,49,
147,NCT03581591,Phase 3,"Hypophosphatemia|Hypophosphatemic Rickets|Pain, Chronic",0,,Protocol NCT03578081v1.0.doc,Statitical Analysis PlanNCT03578081v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy,48,
146,NCT03582007,Phase 3,Pneumonia,0,,Protocol NCT03581591v1.0.doc,Statitical Analysis PlanNCT03581591v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,"Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets",47,
145,NCT03582774,Phase 3,Recurrent Prostate Carcinoma,1,,Protocol NCT03582007v1.0.doc,Statitical Analysis PlanNCT03582007v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas,46,
144,NCT03583151,Phase 3,Stenosing Tenosynovitis,0,,Protocol NCT03582774v1.0.doc,Statitical Analysis PlanNCT03582774v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT],45,
143,NCT03583710,Phase 3,ENSAT Stage I Adrenal Cortex Carcinoma|ENSAT Stage II Adrenal Cortex Carcinoma|ENSAT Stage III Adrenal Cortex Carcinoma,0,,Protocol NCT03583151v1.0.doc,Statitical Analysis PlanNCT03583151v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Corticosteroid vs. Amniotic Fluid Injections in Patients With Trigger Finger,44,
142,NCT03585569,Phase 3,"Multiple Sclerosis|Spasticity, Muscle",0,,Protocol NCT03583710v1.0.doc,Statitical Analysis PlanNCT03583710v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2),43,
141,NCT03586934,Phase 3,Shoulder Pain|Opioid Use,0,,Protocol NCT03585569v1.0.doc,Statitical Analysis PlanNCT03585569v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,""" Treating MS Patients With Lower Extremity Spasticity Using Dysport""",42,
140,NCT03591874,Phase 3,Graft Versus Host Disease|Ocular Surface Disease,0,,Protocol NCT03586934v1.0.doc,Statitical Analysis PlanNCT03586934v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Multimodal Analgesia in Shoulder Arthroplasty,41,
139,NCT03594123,Phase 3,Alzheimer Disease,0,,Protocol NCT03591874v1.0.doc,Statitical Analysis PlanNCT03591874v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease,40,
138,NCT03597464,Phase 3,Lupus Nephritis,0,,Protocol NCT03594123v1.0.doc,Statitical Analysis PlanNCT03594123v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,39,
137,NCT03598426,Phase 3,Hypersensitivity Reactions,0,,Protocol NCT03597464v1.0.doc,Statitical Analysis PlanNCT03597464v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin,38,
136,NCT03602859,Phase 3,Ovarian Cancer,0,,Protocol NCT03598426v1.0.doc,Statitical Analysis PlanNCT03598426v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity,37,
135,NCT03617367,Phase 3,Cervical Dystonia,0,,Protocol NCT03602859v1.0.doc,Statitical Analysis PlanNCT03602859v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer,36,
134,NCT03619850,Phase 3,Chronic Kidney Disease,0,,Protocol NCT03617367v1.0.doc,Statitical Analysis PlanNCT03617367v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS),35,
133,NCT03651128,Phase 3,Multiple Myeloma, Iron Deficiency Anemia,0,,Protocol NCT03619850v1.0.doc,Statitical Analysis PlanNCT03619850v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,"A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)",34
132,NCT03652168,Phase 3,Stress|Psychological Distress,0,,Protocol NCT03651128v1.0.doc,Statitical Analysis PlanNCT03651128v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM),33,
131,NCT03655028,Phase 3,COPD,0,,Protocol NCT03652168v1.0.doc,Statitical Analysis PlanNCT03652168v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Stress Free UC Merced: The Effect of 8 Weeks of Mindfulness App Headspace on Stress in a Sample of University Employees,32,
130,NCT03657433,Phase 3,Iron Deficiency Anemia of Pregnancy,0,,Protocol NCT03655028v1.0.doc,Statitical Analysis PlanNCT03655028v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Increasing Physical Activity in COPD Through Rhythmically Enhanced Music,31,
129,NCT03661996,Phase 3,Knee Osteoarthritis,0,,Protocol NCT03657433v1.0.doc,Statitical Analysis PlanNCT03657433v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy,30,
128,NCT03662282,Phase 3,Cholestasis|Cholestasis of Parenteral Nutrition,0,,Protocol NCT03661996v1.0.doc,Statitical Analysis PlanNCT03661996v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,"A Study to Compare Five Different Treatment Regimens of CNTX-4975 for Participants With Chronic, Moderate-to-Severe Osteoarthritis Pain",29,
127,NCT03667053,Phase 3,Hypoglycemia,0,,Protocol NCT03662282v1.0.doc,Statitical Analysis PlanNCT03662282v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Omegaven as Alternative Parenteral Fat Nutrition,28,
126,NCT03667690,Phase 3,Candidemia|Mycoses|Fungal Infection|Invasive Candidiases,0,,Protocol NCT03667053v1.0.doc,Statitical Analysis PlanNCT03667053v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children,27,
125,NCT03669588,Phase 3,Generalized Myasthenia Gravis,0,,Protocol NCT03667690v1.0.doc,Statitical Analysis PlanNCT03667690v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis,26,
124,NCT03673501,Phase 3,Gastrointestinal Stromal Tumors,0,,Protocol NCT03669588v1.0.doc,Statitical Analysis PlanNCT03669588v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness,25,
123,NCT03673943,Phase 3,Neuroendocrine Tumors,0,,Protocol NCT03673501v1.0.doc,Statitical Analysis PlanNCT03673501v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib,24,
122,NCT03678025,Phase 3,Castration Levels of Testosterone|Metastatic Prostatic Adenocarcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8,0,,Protocol NCT03673943v1.0.doc,Statitical Analysis PlanNCT03673943v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE,23,
121,NCT03678792,Phase 3,Opioid-Related Disorders|Opioid Withdrawal,1,,Protocol NCT03678025v1.0.doc,Statitical Analysis PlanNCT03678025v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer,22,
120,NCT03680911,Phase 3,Anosmia|Head Trauma,0,,Protocol NCT03678792v1.0.doc,Statitical Analysis PlanNCT03678792v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Comparison of Three Opioid Detoxification Treatment Regimens,21,
119,NCT03682224,Phase 3,Non Small Cell Lung Cancer|Lung Cancer Stage 1,0,,Protocol NCT03680911v1.0.doc,Statitical Analysis PlanNCT03680911v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,NAC for Head Trauma-induced Anosmia,20,
118,NCT03683030,Phase 3,Atrial Fibrillation,0,,Protocol NCT03682224v1.0.doc,Statitical Analysis PlanNCT03682224v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients,19,
117,NCT03683186,Phase 3,"PAH|Pulmonary Hypertension|Pulmonary Arterial Hypertension|Hypertension|Connective Tissue Diseases|Familial Primary Pulmonary Hypertension|Vascular Diseases|Cardiovascular Diseases|Hypertension, Pulmonary|Lung Diseases|Respiratory Tract Disease",0,,Protocol NCT03683030v1.0.doc,Statitical Analysis PlanNCT03683030v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation,18,
116,NCT03689712,Phase 3,Oral Mucositis,0,,Protocol NCT03683186v1.0.doc,Statitical Analysis PlanNCT03683186v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Study Evaluating the Long-Term Safety and Efficacy of Ralinepag in Subjects With PAH Via an Open-Label Extension,17,
115,NCT03689946,Phase 3,Cardiovascular Disease|Hyperlipidemia,0,,Protocol NCT03689712v1.0.doc,Statitical Analysis PlanNCT03689712v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer,16,
114,NCT03690388,Phase 3,Differentiated Thyroid Cancer,0,,Protocol NCT03689946v1.0.doc,Statitical Analysis PlanNCT03689946v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Effect of Evolocumab on Coronary Artery Plaque Volume and Composition by CCTA and Microcalcification by F18-NaF PET,15,
113,NCT03694353,Phase 3,Phenylketonuria (PKU),0,,Protocol NCT03690388v1.0.doc,Statitical Analysis PlanNCT03690388v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy,14,
112,NCT03700788,Phase 3,Apical Periodontitis,0,,Protocol NCT03694353v1.0.doc,Statitical Analysis PlanNCT03694353v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Study to Evaluate the Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU,13,
111,NCT03702920,Phase 3,Acute-On-Chronic Liver Failure,0,,Protocol NCT03700788v1.0.doc,Statitical Analysis PlanNCT03700788v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,2% Chlorhexidine (CHX) vs CaOH2 (CH) Calcium Hydroxide Paste as an Intracanal Medicament,12,
110,NCT03703206,Phase 3,"Knee Arthroplasty, Total",0,,Protocol NCT03702920v1.0.doc,Statitical Analysis PlanNCT03702920v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%,11,
109,NCT03706053,Phase 3,Septic Shock,0,,Protocol NCT03703206v1.0.doc,Statitical Analysis PlanNCT03703206v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,ACB+IPACK vs. ACB in TKA,10,
108,NCT03707392,Phase 3,Ileostomy - Stoma|Colostomy Stoma,0,,Protocol NCT03706053v1.0.doc,Statitical Analysis PlanNCT03706053v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Midodrine Use in Septic Shock,9,
107,NCT03710889,Phase 3,"Osteoporosis, Postmenopausal|Osteoporosis|Osteoporosis Vertebral|Osteoporosis Risk|Osteoporosis Fracture|Osteoporosis Localized to Spine|Osteoporosis, Age-Related|Osteoporosis Senile|Osteoporosis of Vertebrae",0,,Protocol NCT03707392v1.0.doc,Statitical Analysis PlanNCT03707392v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Randomized Trial of Inpatient Stoma-Nurse Teaching Versus Stoma Teaching Video Combined With Inpatient Stoma-Nurse Teaching,8,
106,NCT03714373,Phase 3,Prader-Willi Syndrome,0,,Protocol NCT03710889v1.0.doc,Statitical Analysis PlanNCT03710889v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Early Effects of Abaloparatide on Tissue-based Indices of Bone Formation and Resorption,7,
105,NCT03715465,Phase 3,Delayed Sleep Phase Syndrome,0,,Protocol NCT03714373v1.0.doc,Statitical Analysis PlanNCT03714373v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Open-Label Extension Study of Diazoxide Choline in Patients With Prader-Willi Syndrome,6,
104,NCT03729362,Phase 3,Pompe Disease (Late-onset),0,,Protocol NCT03715465v1.0.doc,Statitical Analysis PlanNCT03715465v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,The Clinical Utility of Measuring the Circadian Clock in Treatment of Delayed Sleep-Wake Phase Disorder,5,
103,NCT03729804,Phase 3,Multiple Myeloma,0,,Protocol NCT03729362v1.0.doc,Statitical Analysis PlanNCT03729362v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD,4,
102,NCT03733444,Phase 3,Idiopathic Pulmonary Fibrosis,0,,Protocol NCT03729804v1.0.doc,Statitical Analysis PlanNCT03729804v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,"Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)",3,
101,NCT03736447,Phase 3,Peanut Allergy,0,,Protocol NCT03733444v1.0.doc,Statitical Analysis PlanNCT03733444v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard Medical Treatment,2,
100,NCT03751631,Phase 3,Mydriasis,1,,Protocol NCT03736447v1.0.doc,Statitical Analysis PlanNCT03736447v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Peanut Oral Immunotherapy Study of Early Intervention for Desensitization,1,
93,NCT03741673,Phase 3,Malignant Neoplasm|Metastatic Malignant Neoplasm in the Brain,0,pdf,Protocol NCT03751631v1.0.doc,Statitical Analysis PlanNCT03751631v1.0.doc,2019-04-06 00:26:41,2019-04-06 00:26:41,Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation,94,
99,NCT03743636,Phase 3,Peripheral Artery Disease,0,pdf,Protocol NCT03741673v1.0.doc,Statitical Analysis PlanNCT03741673v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:41,Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases,100,
98,NCT03746522,Phase 3,Bardet Biedl Syndrome (BBS)|Alström Syndrome (AS),0,pdf,Protocol NCT03743636v1.0.doc,Statitical Analysis PlanNCT03743636v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:41,Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease,99,
97,NCT03749096,Phase 3,Stiff-Person Syndrome,0,pdf,Protocol NCT03746522v1.0.doc,Statitical Analysis PlanNCT03746522v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:41,"Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity",98,
96,NCT03750552,Phase 3,Symptomatic Neurogenic Orthostatic Hypotension,0,pdf,Protocol NCT03749096v1.0.doc,Statitical Analysis PlanNCT03749096v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:41,Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome (SPS) Spectrum Disorders.,97,
95,NCT03751124,Phase 3,Uterine Leiomyoma|Uterine Fibroids,0,pdf,Protocol NCT03750552v1.0.doc,Statitical Analysis PlanNCT03750552v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:41,Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure,96,
94,NCT03612869,Phase 2|Phase 3,Mucopolysaccharidosis Type IIIA,1,pdf,Protocol NCT03751124v1.0.doc,Statitical Analysis PlanNCT03751124v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:41,Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids,95,
92,NCT03275402,Phase 2|Phase 3,Neuroblastoma|CNS Metastases|Leptomeningeal Metastases,0,pdf,Protocol NCT03612869v1.0.doc,Statitical Analysis PlanNCT03612869v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Study of AAVrh10-h.SGSH Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA),93,
91,NCT03275350,Phase 2|Phase 3,Opioid-use Disorder|Hiv,0,pdf,Protocol NCT03275402v1.0.doc,Statitical Analysis PlanNCT03275402v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases,92,
90,NCT03088813,Phase 2|Phase 3,Small Cell Lung Cancer,0,pdf,Protocol NCT03275350v1.0.doc,Statitical Analysis PlanNCT03275350v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up,91,
89,NCT03337724,Phase 2|Phase 3,Breast Cancer,0,pdf,Protocol NCT03088813v1.0.doc,Statitical Analysis PlanNCT03088813v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer,90,
88,NCT03389555,Phase 2|Phase 3,Sepsis|Septic Shock|Metabolic Disturbance,0,pdf,Protocol NCT03337724v1.0.doc,Statitical Analysis PlanNCT03337724v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer",89,
87,NCT03398148,Phase 2|Phase 3,Ulcerative Colitis (UC),1,pdf,Protocol NCT03389555v1.0.doc,Statitical Analysis PlanNCT03389555v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,"Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial",88,
86,NCT03410693,Phase 2|Phase 3,"Carcinoma, Transitional Cell",0,pdf,Protocol NCT03398148v1.0.doc,Statitical Analysis PlanNCT03398148v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy",87,
85,NCT03414983,Phase 2|Phase 3,Colorectal Cancer,0,pdf,Protocol NCT03410693v1.0.doc,Statitical Analysis PlanNCT03410693v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma,86,
84,NCT03435796,Phase 2|Phase 3,Neoplasms,0,pdf,Protocol NCT03414983v1.0.doc,Statitical Analysis PlanNCT03414983v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread,85,
83,NCT03446001,Phase 2|Phase 3,Alzheimer Disease,0,pdf,Protocol NCT03435796v1.0.doc,Statitical Analysis PlanNCT03435796v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells,84,
82,NCT03452943,Phase 2|Phase 3,TOURETTE SYNDROME,0,pdf,Protocol NCT03446001v1.0.doc,Statitical Analysis PlanNCT03446001v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Safety and Efficacy of TRx0237 in Subjects With Early Alzheimer's Disease,83,
81,NCT03470922,Phase 2|Phase 3,Melanoma,0,pdf,Protocol NCT03452943v1.0.doc,Statitical Analysis PlanNCT03452943v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Alternatives for Reducing Tics in TS: A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents.,82,
80,NCT03482635,Phase 2|Phase 3,"Colitis, Ulcerative",1,pdf,Protocol NCT03470922v1.0.doc,Statitical Analysis PlanNCT03470922v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma,81,
79,NCT03533582,Phase 2|Phase 3,Childhood Hepatocellular Carcinoma|Childhood Malignant Liver Neoplasm|Elevated Alpha-Fetoprotein|Hepatoblastoma|SMARCB1 Gene Mutation,0,pdf,Protocol NCT03482635v1.0.doc,Statitical Analysis PlanNCT03482635v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,BI 655130 Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis,80,
78,NCT03552276,Phase 2|Phase 3,Psoriatic Arthritis|Ankylosing Spondylitis|Non-Radiographic Axial Spondyloarthritis,0,pdf,Protocol NCT03533582v1.0.doc,Statitical Analysis PlanNCT03533582v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery,79,
77,NCT03570749,Phase 2|Phase 3,Alopecia Areata,1,pdf,Protocol NCT03552276v1.0.doc,Statitical Analysis PlanNCT03552276v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.,78,
76,NCT03605667,Phase 2|Phase 3,Alzheimer Disease,0,pdf,Protocol NCT03570749v1.0.doc,Statitical Analysis PlanNCT03570749v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata,77,
75,NCT03614663,Phase 2|Phase 3,Fragile X Syndrome,0,pdf,Protocol NCT03605667v1.0.doc,Statitical Analysis PlanNCT03605667v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Study of BHV-4157 in Alzheimer's Disease,76,
74,NCT03732638,Phase 2|Phase 3,Migraine,0,pdf,Protocol NCT03614663v1.0.doc,Statitical Analysis PlanNCT03614663v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX),75,
73,NCT03691844,Phase 2|Phase 3,"Osteoarthritis, Knee",0,pdf,Protocol NCT03732638v1.0.doc,Statitical Analysis PlanNCT03732638v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults,74,
72,NCT03692312,Phase 2|Phase 3,Congenital Myotonic Dystrophy,0,pdf,Protocol NCT03691844v1.0.doc,Statitical Analysis PlanNCT03691844v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,AMZ001 for the Treatment of Knee Osteoarthritis Symptoms,73,
71,NCT03475875,Phase 2|Phase 3,Correction of Refraction Error|Attenuation of Bright Light,0,pdf,Protocol NCT03692312v1.0.doc,Statitical Analysis PlanNCT03692312v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy,72,
70,NCT03497975,Phase 2|Phase 3,Prurigo Nodularis,0,pdf,Protocol NCT03475875v1.0.doc,Statitical Analysis PlanNCT03475875v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Contact Lenses With New UV-blocker Manufactured With Different Techniques,71,
69,NCT03370120,Phase 2|Phase 3,Drug-Resistant Epilepsy|Focal-Onset Seizures,0,pdf,Protocol NCT03497975v1.0.doc,Statitical Analysis PlanNCT03497975v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,PRISM Study-Pruritus Relief Through Itch Scratch Modulation,70,
68,NCT03710122,Phase 2|Phase 3,Primary Sclerosing Cholangitis,1,pdf,Protocol NCT03370120v1.0.doc,Statitical Analysis PlanNCT03370120v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy,69,
67,NCT02314988,Phase 2|Phase 3,Spinal Injuries|Spinal Deformity,0,pdf,Protocol NCT03710122v1.0.doc,Statitical Analysis PlanNCT03710122v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Vancomycin for Primary Sclerosing Cholangitis,68,
66,NCT03086993,Phase 2|Phase 3,Bile Duct Cancer|Intrahepatic Cholangiocarcinoma,0,pdf,Protocol NCT02314988v1.0.doc,Statitical Analysis PlanNCT02314988v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Tranexamic Acid to Reduce Blood Loss in Spine Trauma Surgery,67,
65,NCT03292731,Phase 2|Phase 3,Preterm Birth,0,pdf,Protocol NCT03086993v1.0.doc,Statitical Analysis PlanNCT03086993v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma,66,
64,NCT03565666,Phase 2|Phase 3,Type1diabetes,0,pdf,Protocol NCT03292731v1.0.doc,Statitical Analysis PlanNCT03292731v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth,65,
63,NCT03651765,Phase 2|Phase 3,Obesity Associated With Defects in Leptin-melanocortin Pathway,0,pdf,Protocol NCT03565666v1.0.doc,Statitical Analysis PlanNCT03565666v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,The Insulin-Only Bionic Pancreas Bridging Study,64,
62,NCT03172026,Phase 2|Phase 3,Stroke,0,pdf,Protocol NCT03651765v1.0.doc,Statitical Analysis PlanNCT03651765v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Long Term Extension Trial of Setmelanotide,63,
61,NCT03524339,Phase 2|Phase 3,Urinary Retention|Lower Urinary Tract Symptoms|Stress Urinary Incontinence|Pelvic Organ Prolapse,0,pdf,Protocol NCT03172026v1.0.doc,Statitical Analysis PlanNCT03172026v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Maraviroc to Augment Rehabilitation Outcomes After Stroke,62,
60,NCT03593902,Phase 2|Phase 3,Systemic Sclerosis|Scleroderma,0,pdf,Protocol NCT03524339v1.0.doc,Statitical Analysis PlanNCT03524339v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery,61,
59,NCT02489019,Phase 2|Phase 3,Hypotension,0,pdf,Protocol NCT03593902v1.0.doc,Statitical Analysis PlanNCT03593902v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Cardiac Safe Transplants for Systemic Sclerosis,60,
58,NCT02847013,Phase 2|Phase 3,Pain,0,pdf,Protocol NCT02489019v1.0.doc,Statitical Analysis PlanNCT02489019v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Fentanyl Effect on Blood Pressure in Elderly Patients After Induction of General Anesthesia,59,
57,NCT03005379,Phase 2|Phase 3,Clostridium Difficile Infection,0,pdf,Protocol NCT02847013v1.0.doc,Statitical Analysis PlanNCT02847013v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,The Use of Liposomal Bupivacaine in TAP Blocks for Women Undergoing Cesarean Section,58,
56,NCT03223220,Phase 2|Phase 3,Acute Ischemic Stroke,0,pdf,Protocol NCT03005379v1.0.doc,Statitical Analysis PlanNCT03005379v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH),57,
55,NCT03238157,Phase 2|Phase 3,Radiation Retinopathy,0,pdf,Protocol NCT03223220v1.0.doc,Statitical Analysis PlanNCT03223220v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Quelling of Excitotoxicity in Acute Stroke With Ketamine,56,
54,NCT03244072,Phase 2|Phase 3,Endophthalmitis,0,pdf,Protocol NCT03238157v1.0.doc,Statitical Analysis PlanNCT03238157v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Steroids for Early Treatment of Radiation Retinopathy,55,
53,NCT03321656,Phase 2|Phase 3,End Stage Renal Disease,0,pdf,Protocol NCT03244072v1.0.doc,Statitical Analysis PlanNCT03244072v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery,54,
52,NCT03324607,Phase 2|Phase 3,Copd,0,pdf,Protocol NCT03321656v1.0.doc,Statitical Analysis PlanNCT03321656v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile,53,
51,NCT03339921,Phase 2|Phase 3,Chronic Exertional Compartment Syndrome,0,pdf,Protocol NCT03324607v1.0.doc,Statitical Analysis PlanNCT03324607v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI,52,
50,NCT03348930,Phase 2|Phase 3,Obsessive-Compulsive Disorder,0,pdf,Protocol NCT03339921v1.0.doc,Statitical Analysis PlanNCT03339921v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Botulinum for Chronic Exertional Compartment Syndrome,51,
49,NCT03354611,Phase 2|Phase 3,Breast Cancer,0,pdf,Protocol NCT03348930v1.0.doc,Statitical Analysis PlanNCT03348930v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Tolcapone in Obsessive Compulsive Disorder,50,
48,NCT03359161,Phase 2|Phase 3,Heart Failure,0,pdf,Protocol NCT03354611v1.0.doc,Statitical Analysis PlanNCT03354611v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging,49,
47,NCT03361345,Phase 2|Phase 3,Postinflammatory Hyperpigmentation,0,pdf,Protocol NCT03359161v1.0.doc,Statitical Analysis PlanNCT03359161v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Clinical Utility of Subcutaneous Furosemide in Patients Presenting With Early Signs of Fluid Overload,48,
46,NCT03376984,Phase 2|Phase 3,Dental Pulp Diseases|Dental Pulp Necrosis|Nerve Root Pain Nec,0,pdf,Protocol NCT03361345v1.0.doc,Statitical Analysis PlanNCT03361345v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris,47,
45,NCT03388346,Phase 2|Phase 3,"Prostate Cancer|Prostatic Neoplasm|Prostatic Neoplasms, Castration-Resistant|Prostatic Neoplasm of Uncertain Behavior",0,pdf,Protocol NCT03376984v1.0.doc,Statitical Analysis PlanNCT03376984v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Nanodiamond-Gutta Percha Composite Biomaterials for Root Canal Therapy,46,
44,NCT03389451,Phase 2|Phase 3,"Prostate Cancer|Prostatic Neoplasm|Prostatic Neoplasms, Castration-Resistant|Prostatic Cancer Recurrent|Prostatic Cancer Metastatic",1,pdf,Protocol NCT03388346v1.0.doc,Statitical Analysis PlanNCT03388346v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,68Ga PSMA in Preprostatectomy Patients,45,
43,NCT03395288,Phase 2|Phase 3,Urinary Tract Infections,0,pdf,Protocol NCT03389451v1.0.doc,Statitical Analysis PlanNCT03389451v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer,44,
42,NCT03402152,Phase 2|Phase 3,Bipolar Depression|Suicidal Ideation,0,pdf,Protocol NCT03395288v1.0.doc,Statitical Analysis PlanNCT03395288v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Nutraceutical Efficacy for rUTI,43,
41,NCT03408483,Phase 2|Phase 3,Total Hip Arthroplasty,0,pdf,Protocol NCT03402152v1.0.doc,Statitical Analysis PlanNCT03402152v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,NRX101 Glx Biomarker Validation Study,42,
40,NCT03412591,Phase 2|Phase 3,Sleep Disturbance|Craving|Cortisol,0,pdf,Protocol NCT03408483v1.0.doc,Statitical Analysis PlanNCT03408483v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Quadratus Lumborum Block Versus Control for Total Hip Arthroplasty,41,
39,NCT03421808,Phase 2|Phase 3,Depression, Hypersecretion,0,pdf,Protocol NCT03412591v1.0.doc,Statitical Analysis PlanNCT03412591v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial,40
38,NCT03452072,Phase 2|Phase 3,Wound of Skin|Wound Heal|Wound Open|Surgical Wound,0,pdf,Protocol NCT03421808v1.0.doc,Statitical Analysis PlanNCT03421808v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,EEG Synchronized TMS Trial for Depression,39,
37,NCT03452917,Phase 2|Phase 3,Out-Of-Hospital Cardiac Arrest,0,pdf,Protocol NCT03452072v1.0.doc,Statitical Analysis PlanNCT03452072v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds,38,
36,NCT03455218,Phase 2|Phase 3,Inflammation|Platelet Dysfunction,0,pdf,Protocol NCT03452917v1.0.doc,Statitical Analysis PlanNCT03452917v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest,37,
35,NCT03476876,Phase 2|Phase 3,Diabetic Foot Ulcer|Deep Diabetic Foot Ulcer,0,pdf,Protocol NCT03455218v1.0.doc,Statitical Analysis PlanNCT03455218v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation,36,
34,NCT03477006,Phase 2|Phase 3,Hemorrhagic Shock,0,pdf,Protocol NCT03476876v1.0.doc,Statitical Analysis PlanNCT03476876v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Foot Ulcers,35,
33,NCT03479476,Phase 2|Phase 3,"Fragile X Syndrome|Fragile X Mental Retardation Syndrome|Mental Retardation, X Linked|Genetic Diseases, X-Linked|Trinucleotide Repeat Expansion|Fra(X) Syndrome|Intellectual Disability|FXS|Neurobehavioral Manifestations|Sex Chromosome Disorders",0,pdf,Protocol NCT03477006v1.0.doc,Statitical Analysis PlanNCT03477006v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Pragmatic Prehospital Group O Whole Blood Early Resuscitation Trial,34,
32,NCT03503513,Phase 2|Phase 3,Urinary Tract Infections|Spinal Cord Injuries|Spinal Cord Diseases|Neurogenic Bladder,0,pdf,Protocol NCT03479476v1.0.doc,Statitical Analysis PlanNCT03479476v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,A Trial of Metformin in Individuals With Fragile X Syndrome,33,
31,NCT03504046,Phase 2|Phase 3,Type 1 Diabetes Mellitus,0,pdf,Protocol NCT03503513v1.0.doc,Statitical Analysis PlanNCT03503513v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury,32,
30,NCT03506347,Phase 2|Phase 3,Arthropathy of Knee Joint,0,pdf,Protocol NCT03504046v1.0.doc,Statitical Analysis PlanNCT03504046v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Safety and Feasibility Evaluation of the APS APP,31,
29,NCT03508440,Phase 2|Phase 3,Bell's Palsy|Facial Nerve Paresis,0,pdf,Protocol NCT03506347v1.0.doc,Statitical Analysis PlanNCT03506347v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement,30,
28,NCT03508934,Phase 2|Phase 3,"Diabetes Mellitus, Type 2|Hypoglycemia",0,pdf,Protocol NCT03508440v1.0.doc,Statitical Analysis PlanNCT03508440v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Intratympanic Steroid for Bell's Palsy,29,
27,NCT03519061,Phase 2|Phase 3,"Chronic Sinus Infection|Chronic Sinusitis|Chronic Sinusitis - Ethmoidal, Posterior|Chronic Sinus Congestion",0,pdf,Protocol NCT03508934v1.0.doc,Statitical Analysis PlanNCT03508934v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Continuous Glucose Monitoring Devices in Hospitalized Veterans With Diabetes,28,
26,NCT03521141,Phase 2|Phase 3,Tobacco Use Cessation,0,pdf,Protocol NCT03519061v1.0.doc,Statitical Analysis PlanNCT03519061v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Impact of Budesonide Irrigations on Patients With Chronic Rhinosinusitis and Impact on Sinus Surgery Rates,27,
25,NCT03523728,Phase 2|Phase 3,"Polycystic Kidney, Autosomal Dominant",0,pdf,Protocol NCT03521141v1.0.doc,Statitical Analysis PlanNCT03521141v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,PRecision Interventions for SMoking in the SCCS,26,
24,NCT03530800,Phase 2|Phase 3,Trichotillomania,0,pdf,Protocol NCT03523728v1.0.doc,Statitical Analysis PlanNCT03523728v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,"Study of Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)",25,
23,NCT03539900,Phase 2|Phase 3,Binge-Eating Disorder,1,pdf,Protocol NCT03530800v1.0.doc,Statitical Analysis PlanNCT03530800v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Dronabinol in Trichotillomania,24,
22,NCT03548610,Phase 2|Phase 3,Wound of Skin|Non-melanoma Skin Cancer|Skin Graft Complications|Wound of Lower Leg|Wound of Knee,0,pdf,Protocol NCT03539900v1.0.doc,Statitical Analysis PlanNCT03539900v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder,23,
21,NCT03553758,Phase 2|Phase 3,Anesthesia,0,pdf,Protocol NCT03548610v1.0.doc,Statitical Analysis PlanNCT03548610v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Efficacy and Safety of a Nanofat-seeded Biological Scaffold in Healing Lower Limb Surgical Defects,22,
20,NCT03570931,Phase 2|Phase 3,Infantile Neuroaxonal Dystrophy,0,pdf,Protocol NCT03553758v1.0.doc,Statitical Analysis PlanNCT03553758v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,EEG Studies of Ketamine General Anesthesia,21,
19,NCT03572049,Phase 2|Phase 3,Fungal Infection,0,pdf,Protocol NCT03570931v1.0.doc,Statitical Analysis PlanNCT03570931v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy,20,
18,NCT03575572,Phase 2|Phase 3,Single-ventricle|Heart Diseases,0,pdf,Protocol NCT03572049v1.0.doc,Statitical Analysis PlanNCT03572049v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole,19,
17,NCT03579160,Phase 2|Phase 3,Wound of Skin|Wound Heal|Surgical Wound|Full Thickness Skin Graft Healing,1,pdf,Protocol NCT03575572v1.0.doc,Statitical Analysis PlanNCT03575572v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Colchicine in Postoperative Fontan Patients,18,
16,NCT03580707,Phase 2|Phase 3,Photosensitive Epilepsy,0,pdf,Protocol NCT03579160v1.0.doc,Statitical Analysis PlanNCT03579160v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes,17,
15,NCT03583255,Phase 2|Phase 3,Advanced Malignant Neoplasm|Cancer Fatigue|Metastatic Malignant Neoplasm|Recurrent Malignant Neoplasm,0,pdf,Protocol NCT03580707v1.0.doc,Statitical Analysis PlanNCT03580707v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint,16,
14,NCT03595254,Phase 2|Phase 3,Suicidal Ideation|Depression|Anxiety,0,pdf,Protocol NCT03583255v1.0.doc,Statitical Analysis PlanNCT03583255v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,"Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Participants With Advanced, Metastatic, or Recurrent Cancer",15,
13,NCT03607175,Phase 2|Phase 3,Chronic Rhinosinusitis|Nasal Polyps,0,pdf,Protocol NCT03595254v1.0.doc,Statitical Analysis PlanNCT03595254v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Digital Cognitive Behavior Therapy Program for Suicide Prevention,14,
12,NCT03632109,Phase 2|Phase 3,Pharyngeal Gonococcal Infection,0,pdf,Protocol NCT03607175v1.0.doc,Statitical Analysis PlanNCT03607175v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Adjunctive Treatment for Chronic Rhinosinusitis With Nasal Polyposis,13,
11,NCT03637816,Phase 2|Phase 3,Anorexia|Non-Small Cell Lung Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,0,pdf,Protocol NCT03632109v1.0.doc,Statitical Analysis PlanNCT03632109v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Gent for Pharyngeal Gonorrhea (GC),12,
10,NCT03640507,Phase 2|Phase 3,Cesarean Section,1,pdf,Protocol NCT03637816v1.0.doc,Statitical Analysis PlanNCT03637816v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Anamorelin Hydrochloride in Reducing Anorexia in Participants With Advanced Non-small Cell Lung Cancer,11,
9,NCT03652948,Phase 2|Phase 3,Depression|Depressive Symptoms, Infection|Surgical Site Infection,0,pdf,Protocol NCT03640507v1.0.doc,Statitical Analysis PlanNCT03640507v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Vaginal Preparation With Chlorhexidine-alcohol vs. Povidine-iodine vs. Saline,10
8,NCT03691792,Phase 2|Phase 3,Seasonal Affective Disorder,0,pdf,Protocol NCT03652948v1.0.doc,Statitical Analysis PlanNCT03652948v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Meru Health Ascend Mobile Intervention for Depression in Middle Aged and Older Adults,9,
7,NCT03704922,Phase 2|Phase 3,Sickle Cell Disease,0,pdf,Protocol NCT03691792v1.0.doc,Statitical Analysis PlanNCT03691792v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Optimizing Long-Term Outcomes for Winter Depression With CBT-SAD and Light Therapy,8,
6,NCT03716050,Phase 2|Phase 3,Perfusion,0,pdf,Protocol NCT03704922v1.0.doc,Statitical Analysis PlanNCT03704922v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Age of Blood in Sickle Cell Transfusion,7,
5,NCT03723655,Phase 2|Phase 3,Hypertrophic Cardiomyopathy, Complications,0,pdf,Protocol NCT03716050v1.0.doc,Statitical Analysis PlanNCT03716050v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,"The Effect of Nitroglycerin Ointment, Fluorescent Angiography, and Incisional Negative Pressure Wound Therapy on Mastectomy Skin Flap Perfusion-Related Problems",6
4,NCT03726398,Phase 2|Phase 3,Interstitial Lung Disease|Scleroderma|Pulmonary Hypertension,0,pdf,Protocol NCT03723655v1.0.doc,Statitical Analysis PlanNCT03723655v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM,5,
3,NCT03730129,Phase 2|Phase 3,Secondary Immune Deficiency Disorder,1,pdf,Protocol NCT03726398v1.0.doc,Statitical Analysis PlanNCT03726398v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH,4,
2,NCT03746951,Phase 2|Phase 3,Orthopedic Disorder,0,pdf,Protocol NCT03730129v1.0.doc,Statitical Analysis PlanNCT03730129v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig,3,
,,,,0,pdf,Protocol NCT03746951v1.0.doc,Statitical Analysis PlanNCT03746951v1.0.doc,2019-03-29 15:23:17,2019-04-06 00:26:40,Comparative Evaluation of Lumbar Plexus and Suprainguinal Fascia Iliaca Compartment Blocks,2,
